研究者詳細

顔写真

コマツ　ヒロシ
小松　浩
Hiroshi Komatsu
所属
病院　脳・神経・精神科　精神科
職名
講師
学位

  • 博士（医学） （東北大学大学院医学系研究科）

  • 学士（医学） （東北大学医学部）

学歴 2

  • 東北大学大学院　医学系研究科 精神神経生物学分野

    2004年4月 ～ 2008年3月

  • 東北大学　医学部

    1995年4月 ～ 2001年3月

委員歴 4

  • 日本精神科救急学会　代議員

    2026年7月 ～ 継続中

  • 仙台市精神保健福祉審議会

    2025年1月 ～ 継続中

  • 仙台市精神保健福祉審議会作業部会

    2025年1月 ～ 継続中

  • 日本総合病院精神科医学会　mECT委員会

    2020年4月 ～ 継続中

所属学協会 7

  • 日本神経精神薬理学会

  • 東北医学会

  • 日本総合病院精神医学会

  • 日本統合失調症学会

  • 日本うつ病学会

  • 日本精神科救急学会

  • 日本精神神経学会

︎全件表示 ︎最初の5件までを表示

研究キーワード 1

  • 統合失調症、認知機能、画像遺伝学、バイオマカー、セルフスティグマ、リカバリー、集団心理教育

研究分野 1

  • ライフサイエンス / 精神神経科学 /

受賞 5

  1. 東北医学会奨学賞A

    2022年12月

  2. 精神神経学雑誌投稿奨励賞（東北精神神経学会：地方会部門）

    2022年10月

  3. 優秀発表賞

    2020年10月　日本精神神経学会学術総会

  4. 奨励賞

    2019年10月　日本精神科救急学会学術総会

  5. 優秀発表賞

    2018年6月　日本精神神経学会学術総会

論文 73

  1. Autistic Symptoms in Early Psychosis Are Associated with Mean Diffusivity–Dominant Alterations in White Matter Tracts Implicated in Schizophrenia and Autism Spectrum Disorder 査読有り

    Hiroshi Komatsu, Shu Umezawa, Yutaro Sato, Kazuho Tomimoto, Goh Onoguchi, Kaori Sora, Yoshiaki Shiozawa, Koya Yamauchi, Masato Takahama, Yusuke Utsumi, Yumiko Hamaie, Atsushi Sakuma, Noriyuki Ohmuro, Masahiro Katsura, Fumiaki Ito, Takashi Ono, Nobuhisa Kanahara, Yasuko Tatewaki, Kazunori Matsumoto, Hiroaki Tomita

    Asian Journal of Psychiatry　2026年6月

  2. Autistic symptomatology within the schizophrenia spectrum disorders: A narrative review of cognitive and social correlates and treatment implications 査読有り

    Hiroshi Komatsu, Goh Onoguchi, Yutaro Sato, Yusuke Utsumi, Masato Takahama, Kaori Sora, Yoshiaki Shiozawa, Yuji Onouchi, Takashi Ono, Nobuhisa Kanahara, Hiroaki Tomita

    Schizophrenia Research: Cognition　2026年3月

  3. Persistence of Autistic Symptom Differences by Severity Among Individuals at Clinical High Risk for Psychosis and With First-Episode Psychosis: An 18-Month Longitudinal Follow-Up Study 査読有り

    Hiroshi Komatsu, Yutaro Sato, Kazuho Tomimoto, Goh Onoguchi, Yoshiaki Shiozawa, Kaori Sora, Masato Takahama, Yusuke Utsumi, Yumiko Hamaie, Atsushi Sakuma, Noriyuki Ohmuro, Masahiro Katsura, Fumiaki Ito, Takashi Ono, Nobuhisa Kanahara, Kazunori Matsumoto, Hiroaki Tomita

    Journal of Psychiatric Research　2026年1月

  4. Persistent differences in autistic symptom severity after one year in individuals at clinical high risk of psychosis and with first-episode psychosis 査読有り

    Hiroshi Komatsu, Yutaro Sato, Kazuho Tomimoto, Goh Onoguchi, Kaori Sora, Yoshiaki Shiozawa, Yumiko Hamaie, Atsushi Sakuma, Noriyuki Ohmuro, Masahiro Katsura, Fumiaki Ito, Takashi Ono, Kazunori Matsumoto, Hiroaki Tomita

    Journal of Psychiatric Research　2025年5月

  5. Autistic symptoms and clinical features of individuals at clinical high risk for psychosis and first-episode psychosis 査読有り

    Hiroshi Komatsu, Yutaro Sato, Kazuho Tomimoto, Goh Onoguchi, Tasuku Matsuki, Yumiko Hamaie, Atsushi Sakuma, Noriyuki Ohmuro, Masahiro Katsura, Fumiaki Ito, Takashi Ono, Kazunori Matsumoto, Hiroaki Tomita

    Asian Journal of Psychiatry　2024年12月

  6. Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography 査読有り

    Hiroshi Komatsu, Goh Onoguchi, Steven M. Silverstein, Stefan Jerotic, Atsushi Sakuma, Nobuhisa Kanahara, Yoshihisa Kakuto, Takashi Ono, Takeshi Yabana, Toru Nakazawa, Hiroaki Tomita

    Molecular Psychiatry　2023年12月11日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1038/s41380-023-02340-4 　

    ISSN：1359-4184

    eISSN：1476-5578

    詳細を見る 詳細を閉じる

    Abstract Introduction Abnormal findings on optical coherence tomography (OCT) and electroretinography (ERG) have been reported in participants with schizophrenia spectrum disorders (SSDs). This study aims to reveal the pooled standard mean difference (SMD) in retinal parameters on OCT and ERG among participants with SSDs and healthy controls and their association with demographic characteristics, clinical symptoms, smoking, diabetes mellitus, and hypertension. Methods Using PubMed, Scopus, Web of Science, and PSYNDEX, we searched the literature from inception to March 31, 2023, using specific search terms. This study was registered with PROSPERO (CRD4202235795) and conducted according to PRISMA 2020. Results We included 65 studies in the systematic review and 44 in the meta-analysis. Participants with SSDs showed thinning of the peripapillary retinal nerve fiber layer (pRNFL), macular ganglion cell layer- inner plexiform cell layer, and retinal thickness in all other segments of the macula. A meta-analysis of studies that excluded SSD participants with diabetes and hypertension showed no change in results, except for pRNFL inferior and nasal thickness. Furthermore, a significant difference was found in the pooled SMD of pRNFL temporal thickness between the left and right eyes. Meta-regression analysis revealed an association between retinal thinning and duration of illness, positive and negative symptoms. In OCT angiography, no differences were found in the foveal avascular zone and superficial layer foveal vessel density between SSD participants and controls. In flash ERG, the meta-analysis showed reduced amplitude of both a- and b-waves under photopic and scotopic conditions in SSD participants. Furthermore, the latency of photopic a-wave was significantly shorter in SSD participants in comparison with HCs. Discussion Considering the prior report of retinal thinning in unaffected first-degree relatives and the results of the meta-analysis, the findings suggest that retinal changes in SSDs have both trait and state aspects. Future longitudinal multimodal retinal imaging studies are needed to clarify the pathophysiological mechanisms of these changes and to clarify their utility in individual patient monitoring efforts.

  7. Polydipsia and autistic traits in patients with schizophrenia spectrum disorders 査読有り

    Hiroshi Komatsu, Takashi Ono, Yuji Onouchi, Goh Onoguchi, Yoshinori Maita, Yusuke Ishida, Takahiro Maki, Akiko Oba, Hiroaki Tomita, Yoshihisa Kakuto

    Frontiers in Psychiatry　14　2023年7月6日

    出版者・発行元： Frontiers Media SA

    DOI： 10.3389/fpsyt.2023.1205138 　

    eISSN：1664-0640

    詳細を見る 詳細を閉じる

    Introduction Polydipsia, prevalent in 6%–20% of patients with schizophrenia, results in seclusion and prolonged hospitalization. It is also observed in autistic individuals, with previous studies reporting that autism accounted for 20% of all hospitalized patients with polydipsia. The current study investigated the association between polydipsia and autistic traits in patients with schizophrenia spectrum disorders (SSDs) based on the hypothesis that higher autistic traits would be observed in schizophrenic patients with polydipsia. Methods In the first study (study A), the autism-spectrum quotient [(AQ); Japanese version] scores of long-stay inpatients with and without polydipsia were compared. Furthermore, the association between polydipsia and autistic traits was also examined in short-stay inpatients and outpatients with SSDs (study B). Results Study A showed that patients with polydipsia scored significantly higher on the three AQ subscales (attention switching; communication; and imagination) compared to those without. Study B also showed that patients with polydipsia had significantly higher AQ scores overall and for several subscales compared to those without polydipsia. Binary logistic regression analysis of the combined sample showed that male gender and higher autistic traits were significant predictors of polydipsia. Discussion The study highlights the importance of focusing on such traits to understand the pathogenesis of polydipsia in SSD patients.

  8. Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis 国際誌 査読有り

    Hiroshi Komatsu, Goh Onoguchi, Stefan Jerotic, Nobuhisa Kanahara, Yoshihisa Kakuto, Takashi Ono, Shunichi Funakoshi, Takeshi Yabana, Toru Nakazawa, Hiroaki Tomita

    Molecular Psychiatry　2022年5月2日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1038/s41380-022-01591-x 　

    ISSN：1359-4184

    eISSN：1476-5578

  9. Mediating effects of self-stigma and depression on the association between autistic symptoms and recovery in patients with schizophrenia-spectrum disorders: a cross-sectional study 査読有り

    Hiroshi Komatsu, Takashi Ono, Goh Onoguchi, Hiroaki Tomita, Yoshihisa Kakuto

    BMC Psychiatry　21　(1)　2021年12月

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1186/s12888-021-03472-z 　

    eISSN：1471-244X

    詳細を見る 詳細を閉じる

    <title>Abstract</title><sec> <title>Background</title> Several studies have indicated that self-stigma is associated with depressive symptoms and could be a barrier to recovery in patients with schizophrenia-spectrum disorders. More recently, an association between autistic symptoms and self-stigma was found in schizophrenia-spectrum patients. This study aimed to investigate the association between self-stigma, autistic and depressive symptoms, and recovery in patients with schizophrenia. </sec><sec> <title>Methods</title> In total, 105 participants were evaluated using the Autism Spectrum Quotient, the Internalized Stigma of Mental Illness Scale, the Quick Inventory of Depressive Symptomatology, and the Recovery Assessment Scale to investigate autistic symptoms, self-stigma, depressive symptoms, and recovery, respectively. The relationship between self-stigma, autistic symptoms, depressive symptoms, and recovery was assessed using structural equation modeling analysis. </sec><sec> <title>Results</title> Impaired attention switching, one symptom of autism, was found to positively affect stereotype endorsement, which negatively influenced recovery through depressive symptoms. Moreover, problems with communication skills negatively affected recovery through depressive symptoms. Concerning self-stigma, stereotype endorsement and perceived discrimination had a negative effect on recovery through depressive symptoms, whereas stigma resistance had a direct negative effect on recovery. </sec><sec> <title>Conclusions</title> This study may provide meaningful insight into the psychological structure of recovery and could inform effective interventions for patients with schizophrenia-spectrum disorders. This was a cross-sectionally designed study; therefore, further longitudinal studies are needed to identify the causal relationships between self-stigma, autistic and depressive symptoms, and recovery. </sec>

  10. New long stay 患者の1年後転帰に関連する要因についての予備的検討 査読有り

    小松浩, 大野高志, 米田芳則, 石田雄介, 槙貴浩, 大場綾希子, 森康子, 富田博秋, 角藤芳久

    精神医学　63　(9)　1405-1414　2021年9月

  11. Association Between OLIG2 Gene SNP rs1059004 and Negative Self-Schema Constructing Trait Factors Underlying Susceptibility to Depression 査読有り

    Hiroshi Komatsu, Hikaru Takeuchi, Chiaki Ono, Zhiqian Yu, Yoshie Kikuchi, Yoshihisa Kakuto, Shunichi Funakoshi, Takashi Ono, Ryuta Kawashima, Yasuyuki Taki, Hiroaki Tomita

    Frontiers in Psychiatry　12　2021年3月8日

    出版者・発行元： Frontiers Media SA

    DOI： 10.3389/fpsyt.2021.631475 　

    eISSN：1664-0640

    詳細を見る 詳細を閉じる

    Recent evidence has indicated that the disruption of oligodendrocytes may be involved in the pathogenesis of depression. Genetic factors are likely to affect trait factors, such as characteristics, rather than state factors, such as depressive symptoms. Previously, a negative self-schema had been proposed as the major characteristic of constructing trait factors underlying susceptibility to depression. Thus, the association between a negative self-schema and the functional single nucleotide polymorphism (SNP) rs1059004 in the <italic>OLIG2</italic> gene, which influences <italic>OLIG2</italic> gene expression, white matter integrity, and cerebral blood flow, was evaluated. A total of 546 healthy subjects were subjected to genotype and psychological evaluation using the Beck Depression Inventory-II (BDI-II) and the Brief Core Schema Scale (BCSS). The rs1059004 SNP was found to be associated with the self-schema subscales of the BCSS and scores on the BDI-II in an allele dose-dependent manner, and to have a predictive impact on depressive symptoms via a negative-self schema. The results suggest the involvement of a genetic factor regulating oligodendrocyte function in generating a negative-self schema as a trait factor underlying susceptibility to depression.

  12. Clozapine投与5年後に禁煙した後に好中球減少症を呈した統合失調症の1症例 査読有り

    小松浩, 大野高志, 石田雄介, 角藤芳久

    精神科治療学　36　(3)　2021年

    ISSN：0912-1862

  13. Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter Integrity. 国際誌 査読有り

    Hiroshi Komatsu, Hikaru Takeuchi, Yoshie Kikuchi, Chiaki Ono, Zhiqian Yu, Kunio Iizuka, Yuji Takano, Yoshihisa Kakuto, Shunichi Funakoshi, Takashi Ono, Junko Ito, Yasuto Kunii, Mizuki Hino, Atsuko Nagaoka, Yasushi Iwasaki, Hidenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Hirotsugu Azechi, Noriko Kudo, Ryota Hashimoto, Hirooki Yabe, Mari Yoshida, Yuko Saito, Akiyoshi Kakita, Nobuo Fuse, Ryuta Kawashima, Yasuyuki Taki, Hiroaki Tomita

    Schizophrenia bulletin　46　(6)　1619-1628　2020年12月1日

    DOI： 10.1093/schbul/sbaa049 　

    詳細を見る 詳細を閉じる

    Previous studies have indicated associations between several OLIG2 gene single-nucleotide polymorphisms (SNPs) and susceptibility to schizophrenia among Caucasians. Consistent with these findings, postmortem brain and diffusion tensor imaging studies have indicated that the schizophrenia-risk-associated allele (A) in the OLIG2 SNP rs1059004 predicts lower OLIG2 gene expression in the dorsolateral prefrontal cortex (DLPFC) of schizophrenia patients and reduced white matter (WM) integrity of the corona radiata in normal brains among Caucasians. In an effort to replicate the association between this variant and WM integrity among healthy Japanese, we found that the number of A alleles was positively correlated with WM integrity in some fiber tracts, including the right posterior limb of the internal capsule, and with mean blood flow in a widespread area, including the inferior frontal operculum, orbital area, and triangular gyrus. Because the A allele affected WM integrity in opposite directions in Japanese and Caucasians, we investigated a possible association between the OLIG2 gene SNPs and the expression level of OLIG2 transcripts in postmortem DLPFCs. We evaluated rs1059004 and additional SNPs in the 5' upstream and 3' downstream regions of rs1059004 to cover the broader region of the OLIG2 gene. The 2 SNPs (rs1059004 and rs9653711) had opposite effects on OLIG2 gene expression in the DLPFC in Japanese and Caucasians. These findings suggest ethnicity-dependent opposite effects of OLIG2 gene SNPs on WM integrity and OLIG2 gene expression in the brain, which may partially explain the failures in replicating associations between genetic variants and psychiatric phenotypes among ethnicities.

  14. 「重度かつ慢性」基準案の該当および非該当の長期入院患者のself-stigmaに関する予備的研究 査読有り

    小松 浩, 大野 高志, 米田 芳則, 石田 雄介, 槙 貴浩, 長谷 諭, 大場 綾希子, 手代木 理, 鈴木 明, 森 康子, 庄司 盟子, 藤田 享, 五十嵐 佳代子, 海老名 貴幸, 坂元 洋生, 尾崎 伸也, 本間 竜太, 角藤 芳久

    精神科　37　(4)　448-452　2020年10月

    出版者・発行元： (有)科学評論社

    ISSN：1347-4790

  15. 抗精神病薬持効性注射剤の継続率、再入院予防効果と経口向精神薬の処方変化の検討 査読有り

    小松 浩, 石田 雄介, 秋葉 大輔, 大野 高志, 角藤 芳久

    臨床精神薬理　23　(7)　715-728　2020年7月

    出版者・発行元： (株)星和書店

    ISSN：1343-3474

  16. 急性期病棟入院中および外来通院中の統合失調症患者の自閉スペクトラム症傾向,セルフスティグマ,抑うつ症状とリカバリーとの関連についての検討 査読有り

    小松 浩, 大野 高志, 米田 芳則, 藤田 亨, 鈴木 由美子, 菅原 惣治, 角藤 芳久

    精神医学　62　(4)　455-464　2020年4月

    出版者・発行元： (株)医学書院

    ISSN：0488-1281

    eISSN：1882-126X

  17. Association Between Autistic Symptoms and Self-Stigma in Patients with Schizophrenia Spectrum Disorders. 国際誌 査読有り

    Hiroshi Komatsu, Takashi Ono, Yoshinori Maita, Yusuke Ishida, Tatsuo Kikuchi, Takahiro Maki, Satoshi Hase, Hisakazu Sakurai, Akiko Oba, Osamu Teshirogi, Akira Suzuki, Yasuko Mori, Chikako Shoji, Akira Fujita, Sachiko Takahashi, Takayuki Ebina, Shinya Ozaki, Ryuta Honma, Hiroaki Tomita, Yoshihisa Kakuto

    Neuropsychiatric disease and treatment　16　2553-2561　2020年

    DOI： 10.2147/NDT.S280485 　

    詳細を見る 詳細を閉じる

    Purpose: Self-stigma negatively influences self-esteem, quality of life, self-efficacy, treatment adherence, and recovery in psychiatric patients. By revealing personality traits that influence self-stigma, we can gain useful knowledge for the management of self-stigma. A previous meta-analysis indicated that patients with schizophrenia have higher scores on the Autism-Spectrum Quotient (AQ) than healthy controls. However, the relationship between autistic symptoms and self-stigma in patients with schizophrenia spectrum disorders remains unclear. Therefore, the present study aimed to reveal the association between autistic symptoms and self-stigma in patients with schizophrenia spectrum disorders. Patients and Methods: We recruited 127 patients with schizophrenia spectrum disorders (schizophrenia, schizoaffective disorder, and delusional disorder). We assessed participants' self-stigma and autistic symptoms using the Internalized Stigma for Mental Illness (ISMI) scale and the Autism-Spectrum Quotient (AQ), respectively. The differences in the scores of ISMI and AQ according to patient characteristics were investigated. Multiple regression analysis controlling for age and gender was performed to determine the relationship between the total scores on the AQ and IMSI scale. Results: Female patients showed a higher level of self-stigma than males. Unmarried patients showed a significantly higher score on the AQ than married patients. Multiple regression analysis adjusted for age and gender indicated that the total score on AQ might be a predictor of the overall rating on ISMI in patients with schizophrenia spectrum disorders. Conclusion: This study is the first to reveal the association between autistic symptoms and self-stigma in patients with schizophrenia spectrum disorders. Our results highlight the importance of considering autistic symptoms in the assessment and management of self-stigma in patients with schizophrenia spectrum disorders.

  18. Possible multiple system atrophy with predominant parkinsonism in a patient with chronic schizophrenia: a case report. 国際誌 査読有り

    Hiroshi Komatsu, Masaaki Kato, Teiko Kinpara, Takashi Ono, Yoshihisa Kakuto

    BMC psychiatry　18　(1)　141-141　2018年5月21日

    DOI： 10.1186/s12888-018-1714-y 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Multiple system atrophy (MSA) is an adult-onset, rare, and progressive neurodegenerative disorder characterized by a varying combination of autonomic failure, cerebellar ataxia, and parkinsonism. MSA is categorized as MSA-P with predominant parkinsonism, and as MSA-C with predominant cerebellar features. The prevalence of MSA has been reported to be between 1.86 and 4.9 cases per 100,000 individuals. In contrast, approximately 1% of the population is affected by schizophrenia during their lifetime; therefore, MSA-P comorbidity is very rare in schizophrenic patients. However, when the exacerbation or progression of parkinsonism occurs in patients with schizophrenia treated with antipsychotics, it is necessary to consider rare neurodegenerative disorders, including MSA-P, in the differential diagnosis of parkinsonism. CASE PRESENTATION: A 60-year-old female patient with chronic schizophrenia developed possible MSA-P. She had been treated mainly with typical antipsychotics, and presented with urinary incontinence, nocturnal polyuria, and dysarthria around 2011. In 2014, she developed worsening parkinsonian symptoms and autonomic dysfunction. Although her antipsychotic medication was switched to an atypical antipsychotic and the dose reduced, her parkinsonism was not improved. In 2015, modified electroconvulsive therapy produced slight improvements in the symptoms; however, she shortly returned to her symptomatic state. A combination of cardiac 123I-meta-iodobenzylguanidine scintigraphy and 123I-FP-CIT single-photon emission computed tomography imaging, in addition to brain magnetic resonance imaging findings, helped to discriminate MSA-P from other sources of parkinsonism. L-dopa had been prescribed, but she responded poorly and died in the spring of 2016. CONCLUSIONS: This case report highlights the importance of considering MSA-P in the differential diagnosis for parkinsonism in a patient being treated with antipsychotics for chronic schizophrenia. MSA-P should be considered in patients presenting with worsening and progressing parkinsonism, especially when accompanied by autonomic dysfunction or cerebellar ataxia. Although a definite diagnosis of MSA-P requires autopsy confirmation, a combination of brain magnetic resonance imaging and nuclear medicine scans may help to differentiate suspected MSA-P from the other parkinsonian syndromes. This case also demonstrates that MSA with parkinsonism that is poorly responsive to L-dopa may improve shortly after modified electroconvulsive therapy without worsening psychiatric symptoms.

  19. Decreased response to social defeat stress in μ-opioid-receptor knockout mice. 国際誌 査読有り

    Hiroshi Komatsu, Arihisa Ohara, Kazumasu Sasaki, Hiromi Abe, Hisaki Hattori, F Scott Hall, George R Uhl, Ichiro Sora

    Pharmacology, biochemistry, and behavior　99　(4)　676-82　2011年10月

    DOI： 10.1016/j.pbb.2011.06.008 　

    詳細を見る 詳細を閉じる

    Substantial evidence exists that opioid systems are involved in stress response and that changes in opioid systems in response to stressors affect both reward and analgesia. Reportedly, mice suffering chronic social defeat stress subsequently show aversion to social contact with unfamiliar mice. To further examine the role of opioid systems in stress response, the behavioral and neurochemical effects of chronic social defeat stress (psychosocial stress) were evaluated in μ-opioid-receptor knockout (MOR-KO) mice. Aversion to social contact was induced by chronic social defeat stress in wild-type mice but was reduced in MOR-KO mice. Moreover, basal expression of brain-derived neurotrophic factor (BDNF) mRNA in MOR-KO mice hippocampi was significantly lower than in wild-type mice. Psychosocial stress significantly decreased BDNF mRNA expression in wild-type mice but did not affect BDNF expression in MOR-KO mice; no difference in basal levels of plasma corticosterone was observed. These results suggest that the μ-opioid receptor is involved in the behavioral sequelae of psychosocial stress and consequent regulation of BDNF expression in the hippocampus, and may play an important role in psychiatric disorders for which stress is an important predisposing or precipitating factor, such as depression, posttraumatic stress disorder, and social anxiety disorder.

  20. Transcriptional Changes in Microglial Kcnk2 During Fear Memory Reconsolidation and TREK-1–Associated Regulation of TNF-α in vitro 査読有り

    Runen Cheng, Mai Sakai, Sayako Kanno, Mana Nemoto, Chiaki Ono, Yoshie Kikuchi, Mizuki Hino, Yasuto Kunii, Hiroshi Komatsu, Saya Kikuchi, Motoko Maekawa, Yuji Owada, Takaaki Abe, Hiroaki Tomita, Zhiqian Yu

    Biochemical and Biophysical Research Communications　2026年9月

  21. Posttraumatic Stress Dynamics and 15-Year Persistence in Great East Japan Earthquake Survivors 査読有り

    Xue Li, Hitomi Usukura, Yusuke Utsumi, Moe Seto, Atsushi Sakuma, Kazuho Tomimoto, Terufumi Machida, Yumiko Hamaie, Natsuko Kobayashi, Hiroshi Komatsu, Saya Kikuchi, Shinichi Kuriyama, Naoki Nakaya, Atsushi Hozawa, Yasuto Kunii, Hiroaki Tomita

    JAMA Network Open　9　(8)　e2629441-e2629441　2026年8月14日

    出版者・発行元： American Medical Association (AMA)

    DOI： 10.1001/jamanetworkopen.2026.29441 　

    eISSN：2574-3805

    詳細を見る 詳細を閉じる

    Importance Long-term persistence of posttraumatic stress reactions (PTSRs) is a major public health challenge, yet early prognostic markers for decadal outcomes remain poorly characterized. Specifically, the importance of early symptom fluctuations compared with initial cross-sectional severity is not well understood. Objective To determine whether early postdisaster symptom dynamics within 1 year are associated with persistent, clinically meaningful PTSRs 15 years after the 2011 Great East Japan Earthquake (GEJE). Design, Setting, and Participants This 15-year prospective longitudinal cohort study (2011-2025) included residents of Shichigahama, Miyagi, Japan, aged 20 years or older, who experienced disaster-certified housing destruction after the GEJE. Exposures Early symptom dynamics (2011-2012) based on Impact of Event Scale–Revised (IES-R) scores and classified as (1) high-escalating (IES-R score ≥25 and increasing), (2) high-improving (IES-R score ≥25 and nonincreasing), and (3) nonpersistent early (IES-R score &amp;amp;lt;25 at either wave). Main Outcomes and Measures The primary outcomes were persistent, clinically meaningful PTSRs (IES-R score ≥25) at 15 years. Multivariable logistic regression with 40-fold multiple imputation was used to estimate adjusted odds ratios (aORs). Results Among 1291 participants (685 women [53.1%]; mean [SD] age, 53.9 [16.6] years), group-based trajectory modeling of IES-R scores (2011-2025) identified 5 distinct PTSR patterns. At 15 years, 14.7% of participants (190 participants) had clinically meaningful PTSRs. Symptom escalation was most frequent during the first-to-second year interval compared with all subsequent periods. This trend remained consistent even under stringent escalation criteria (&amp;amp;gt;5-point increase). The high-escalating pattern was the one most associated with 15-year persistence (aOR, 5.31; 95% CI, 3.85-7.32). The prognostic model incorporating early dynamics demonstrated improved discrimination (area under the curve [AUC], 0.756; 95% CI, 0.717-0.763) compared with models using baseline symptom severity alone (AUC, 0.608; 95% CI, 0.600-0.612) or delayed single-point assessments (AUC, 0.726; 95% CI, 0.663-0.738). Conclusions and Relevance In this 15-year cohort study of GEJE survivors, symptom escalation during the first-to-second year interval was identified as the most prevalent pattern and was a factor associated with long-term persistent PTSRs. Because early symptom dynamics offer superior prognostic accuracy compared with single-point assessments, these findings support a serial screening approach during the immediate postdisaster period to optimize risk stratification and early intervention strategies.

  22. Mediating roles of insight and resilience in the relationship between beliefs about auditory verbal hallucinations and functioning in patients with chronic schizophrenia: A preliminary analysis 査読有り

    Nobuhisa Kanahara, Remiko Kobayashi, Kah Kheng Goh, Hiroshi Komatsu, Taisuke Yoshida, Masaomi Iyo

    2026年8月

  23. Hippocampal Structural Changes and Antipsychotic Medication in Schizophrenia Spectrum Disorder: A Systematic Review and Meta-Analysis of Longitudinal MRI Studies Highlighting Current Evidence Gaps 査読有り

    Nobuhisa Kanahara, Hiroshi Kimura, Hiroshi Komatsu, Yuki Shiko, Yohei Kawasaki, Julia M Lappin, Masaomi Iyo

    Current Neuropharmacology　24　2026年7月21日

    出版者・発行元： Bentham Science Publishers Ltd.

    DOI： 10.2174/011570159x457039260706065949 　

    ISSN：1570-159X

    詳細を見る 詳細を閉じる

    Introduction: The hippocampus is among the most affected brain structures in schizophrenia and plays a central role in the core pathology of psychotic disorders. Despite observations thathippocampal structural deficits emerge from the early stages of schizophrenia, it remains unclear howthese changes progress over the disease course and how antipsychotic medication influences them Methods: We conducted a systematic review of longitudinal, volumetric MRI studies of patientswith First-Episode Psychosis (FEP) and those at the Chronic stage (CH), and extracted data onhippocampal volume and antipsychotic medication exposure for meta-analysis. Both the review andthe analysis conformed to PRISMA 2020 guidelines. Results: Eighteen reports were included. Longitudinal analysis of the FEP group revealed no significantchange in hippocampal volume over time (scan interval), likely due to substantial heterogeneityacross studies. By contrast, the CH group exhibited a significantly faster, albeit subtle, reduction inhippocampal volume compared with Healthy Controls (HC). The meta-regression analysis revealedno significant associations between hippocampal volume reduction and any examined factors,including antipsychotic medication exposure, likely reflecting the small number of studies and thepaucity of medication-related data. Discussion: The pace of hippocampal volume change appears to differ between the early and chronicstages. Conclusions: Substantial heterogeneity and insufficient available data in the current literature limitthe ability to draw firm conclusions regarding hippocampal volume changes across disease stages ortheir relationship with antipsychotic medication. The pace of these changes may differ between theFEP and CH stages, but this observation should be interpreted cautiously. Further longitudinal MRIstudies with more detailed and consistent reporting of medication-related variables are needed toclarify these relationships.

  24. Association between initial 30‐day cumulative clozapine dose and risk of agranulocytosis: A nationwide register‐based cohort study

    Yuki Kikuchi, Xue Li, Hiroshi Komatsu, Norio Yasui‐Furukori, Ken Inada, Hiroaki Tomita

    Psychiatry and Clinical Neurosciences　2026年6月15日

    出版者・発行元： Wiley

    DOI： 10.1111/pcn.70092 　

    ISSN：1323-1316

    eISSN：1440-1819

    詳細を見る 詳細を閉じる

    Aims Clozapine‐induced agranulocytosis (CIA) is traditionally considered an idiosyncratic, dose‐independent reaction. However, emerging evidence suggests that clozapine‐related inflammatory events may exhibit dose‐dependent characteristics, leading us to hypothesize that CIA risk may similarly relate to early cumulative exposure. Methods Using Japan's nationwide Clozaril Patient Monitoring Service database (2009–2024), the 30‐day cumulative dose following initiation was calculated for all treated patients. Participants were stratified into quartiles (Q1–Q4). CIA was defined as two consecutive absolute neutrophil counts &lt;500/mm 3 . The incidence of CIA was compared across quartiles using Kaplan–Meier survival curves and Cox proportional hazards models adjusted for age and sex. Results Among 18,189 patients (mean age 42.9 [SD 12.7]; 46.4% female), 138 (0.76%) developed CIA, with no cases occurring within the first 30 days. The incidence rates of CIA in Q1, Q2, Q3, and Q4 were 0.44%, 0.66%, 0.74%, and 1.20%, respectively. Compared with Q1, hazard ratios (HRs) over 180 days were 1.78 (95% confidence interval [CI] 0.96–3.30; P  = 0.0659), 2.01 (95% CI 1.10–3.66; P  = 0.0233), and 3.07 (95% CI 1.74–5.42; P  &lt; 0.001) for Q2, Q3, and Q4, respectively. Male sex and age &gt;40 years were identified as independent risk factors. E ‐values for Q4 HR were 5.59 (point estimate) and 2.88 (95% CI), indicating high robustness against unmeasured confounders such as co‐medications. Conclusions Higher early cumulative clozapine exposure was associated with increased CIA risk. These findings suggest that early exposure may serve as a clinically relevant marker of CIA risk, although causal inference is limited and further research is needed.

  25. A retrospective comparative analysis of the clinical response to clozapine between patients with early and late treatment-resistant schizophrenia 査読有り

    Kazuki Okada, Nobuhisa Kanahara, Yuji Otsuka, Remiko Kobayashi, Hiroshi Yamanaka, Yuri Takaoki, Fumiaki Ito, Hiroshi Komatsu, Taisuke Yoshida, Yuki Kikuchi, Hiroshi Kimura, Takahiro Oiwa, Takashi Ono, Takahisa Saiga, Shingo Noda, Yasunori Oda, Tomihisa Niitsu, Masaomi Iyo

    Journal of Psychiatric Research　2026年5月

  26. Autonomic Nervous System Reactions to Secondary Exposure to Disaster -Related Imagery 査読有り

    Chiaki T. Ono, Hironobu Kato, Yoshie Kikuchi, Zhiqian Yu, Yumiko Hamaie, Mizuki Hino, Kazuho Tomimoto, Hiroshi Komatsu, Saya Kikuchi, Yasuto Kunii, Tomohiro Uchida, Hiroaki Tomita

    Frontiers in Psychiatry　2026年3月

  27. Neural substrates of treatment-resistant schizophrenia and the response to clozapine A structural MRI study in a clinical setting 査読有り

    Yuto Masumo, Nobuhisa Kanahara, Yuji Otsuka, Yusuke Sudo, Teruyuki Ishii, Hirotaka Sato, Keita Idemoto, Hiroshi Komatsu, Yuko Fujita, Yasunori Oda, Tomihisa Niitsu, Yoshiyuki Hirano, Masaomi Iyo

    PLOS One　2026年3月

  28. Sex Differences in the Risk of Autistic-Related Traits in Toddlers Born to Mothers with Perinatal Depression: Evidence from Human Cohort and Mouse Study 査読有り

    Changrong Duan, Zhiqian Yu, Xue Li, Mai Sakai, Yuko Maejima, Kenju Shimomura, Tomoyuki Furuyashiki, Saya Kikuchi, Natsuko Kobayashi, Kazuto Sasaki, Tasuku Matsuki, Hiroshi Komatsu, Mizuki Hino, Yasuto Kunii, Tomoko Kasahara, Mami Ishikuro, Keiko Murakami, Masatsugu Orui, Takaaki Abe, Fuji Nagami, Nobuo Fuse, Soichi Ogishima, Kengo Kinoshita, Masayuki Yamamoto, Naoki Nakaya, Atsushi Hozawa, Taku Obara, Shinichi Kuriyama, Hiroaki Tomita

    Molecular Psychiatry　2025年12月

  29. Ethnicity-based personalized clozapine titration strategies for prevention of clozapine-induced inflammation: Recommendations based on evidence from the Japanese population 査読有り

    Yuki Kikuchi, Bunichiro Onodera, Hiroshi Komatsu, Hiroaki Tomita

    CNS Drugs　2025年12月

  30. Associations between depressive symptoms and frequency, intensity, duration, and style of walking in survivors of the Great East Japan Earthquake 査読有り

    Yusuke Utsumi, Moe Seto, Hitomi Usukura, Yumiko Hamaie, Atsushi Sakuma, Kazuho Tomimoto, Hiroshi Komatsu, Saya Kikuchi, Yumi Sugawara, Shinichi Kuriyama, Naoki Nakaya, Atsushi Hozawa, Yasuto Kunii, Hiroaki Tomita

    Psychiatry and Clinical Neurosciences Reports　4　(3)　2025年9月14日

    出版者・発行元： Wiley

    DOI： 10.1002/pcn5.70178 　

    ISSN：2769-2558

    eISSN：2769-2558

    詳細を見る 詳細を閉じる

    Abstract Background In post‐disaster communities, an association between decreased walking activity and depressive symptoms has been reported. This study aimed to identify the associations between the frequency, intensity, time, and type (or style) (FITT) of walking and depressive symptoms. Method The 2018 survey of a cohort study was used to examine 924 individuals aged 20 years or older who were severely affected by the Great East Japan Earthquake. Participants were asked whether they walked intending to improve their health (health‐conscious walkers: N = 335) and were cautious about their walking parameters. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale (CES‐D), and multivariate logistic regression analysis was used to evaluate the association between paying attention to FITT elements and depressive symptoms. Results In health‐conscious walkers, the multivariate model showed that female (odds ratio [OR], 2.45; 95% confidence interval [CI], 1.24–4.84) and paying attention to posture during walking (OR, 0.41; 95% CI, 0.21–0.81) were significantly associated with depressive symptoms (CES‐D ≥ 16). In non‐health‐conscious walkers, evaluating multiple variables, including walking duration, showed that only a walking duration of less than 30 min per day (OR, 2.06; 95% CI, 1.19–3.56) was associated with depressive symptoms. Conclusions The current study indicated that paying attention to posture during walking had a significant negative association with depressive symptoms, suggesting that paying attention to posture while walking may be beneficial for mental health well‐being. These findings may help improve the mental health of communities affected by a disaster through an intervention to promote regular walking.

  31. Calculation of approximate heart rate variability indicators based on low-resolution heart rate data provided by widely used commercially available wearable devices 査読有り

    Xue Li, Goh Onoguchi, Hiroshi Komatsu, Chiaki Ono, Noriko Warita, Zhiqian Yu, Atsuko Nagaoka, Sho Horikoshi, Kenji Iwabuchi, Kohei Fuji, Mizuki Hino, Yuta Takahashi, Hisashi Ohseto, Natsuko Kobayashi, Saya Kikuchi, Yasuto Kunii, Taku Obara, Shinichi Kuriyama, Noriyasu Homma, Parashkev Nachev, Akinori Ito, Hiroaki Tomita

    Biomedical Signal Processing and Control　2025年8月

  32. Elevated neutrophil-to-lymphocyte ratios correlate with increased clozapine concentration-to-dose ratios during titration 査読有り

    Bunichiro Onodera, Mutsumi Sakata, Kazuro Ikawa, Daisuke Kume, Naoki Horikawa, Hiroshi Komatsu, Takuhiro Yamaguchi, Hiroaki Tomita, Yuki Kikuchi

    Schizophrenia　2025年7月

  33. Higher clozapine concentration-to-dose ratios at week 1 after initiation are associated with increased risk of clozapine-associated fever in Japanese patients with schizophrenia 査読有り

    Yuki Kikuchi, Hiroaki Tanifuji, Mutsumi Sakata, Kazuro Ikawa, Daisuke Kume, Naoki Horikawa, Sota Ueno, Yoshifumi Onuma, Masato Ishihara, Bunichiro Onodera, Takeshi Toraiwa, Hiroshi Komatsu, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Hiroaki Tomita

    Frontiers in Psychiatry　2025年5月

  34. Weekly Changes in the Clozapine Concentration-to-Dose Ratio During Clozapine Titration in Japanese Patients with Schizophrenia 査読有り

    Yuki KIkuchi, Mutsumi Sakata, Kazuro Ikawa, Daisuke Kume, Naoki Horikawa, Hiroshi Komatsu, Hiroaki Tomita

    Journal of Clinical Psychopharmacology　2025年3月

  35. COVID-19 outbreak in a ward led three patients to discontinue clozapine due to neutropenia: Call for urgent considerations regarding clozapine regulation in Japan 査読有り

    Yuki Kikuchi, Sota Ueno, Bunichiro Onodera, Hiroaki Tanifuji, Hiroshi Komatsu, Hiroaki Tomita

    Schizophrenia Research　2025年2月

    DOI： 10.1016/j.schres.2025.01.024 　

  36. Relationship between clozapine-induced inflammation and eosinophilia: A retrospective cohort study 査読有り

    Yuki Kikuchi, Yuji Otsuka, Fumiaki Ito, Yuji Yada, Hiroaki Tanifuji, Hiroshi, Komatsu, Hiroaki Tomi

    Schizophrenia Bulletin　2024年12月

  37. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk 査読有り

    Yuki Kikuchi, Hiroshi Komatsu, Hiroaki Tomita

    JAMA Psychiatry　2024年10月23日

  38. High frequency of clozapine-associated myocarditis and troponin elevation: Need for slower titration prospective studies Mental Health Clinician 査読有り

    Yuki Kikuchi, Bunichiro Onodera, Hiroshi Komatsu, Hiroaki Tomita

    Mental Health Clinician　2024年7月

  39. Development of a simultaneous LC-MS/MS analytical method for plasma 16 antipsychotics approved in Japan and 4 drug metabolites 査読有り

    Masamitsu Maekawa, Maki Yokota, Toshihiro Sato, Yu Sato, Masaki Kumondai, Yuji Sato, Masato Suzuka, Daisuke Kobayashi, Kotaro Sekimoto, Masaki Matsuura, Masafumi Kikuchi, Hiroshi Komatsu, Kumiko Fujii, Yuji Ozeki, Hiroaki Tomita, Nariyasu Mano

    Analytical Sciences　2024年5月

  40. Obesity as a potential confounder of clozapine-induced myocarditis in the Hunter region of Australia 査読有り

    Yuki Kikuchi, Hiroshi Komatsu, Hiroaki Tomita

    Schizophrenia Research　2024年3月

  41. Effect of concomitant use of valproic acid during clozapine initiation on clozapine-induced inflammation among Japanese patients with schizophrenia 査読有り

    Yuki Kikuchi, Hiroshi Komatsu, Yuji Otsuka, Fumiaki Ito, Yuji Yada, Hiroaki Tanifuji, Hiroaki Tomita

    Psychiatry Research　2024年2月

  42. Patterns of C-reactive protein trends during clozapine titration and the onset of clozapine-induced inflammation: A case series of weekly and daily C-reactive protein monitoring 査読有り

    Yuki Kikuchi, Hiroaki Tanifuji, Sota Ueno, Yoshifumi Onuma, Masatomo Goto, Masato Ishihara, Takeshi Toraiwa, Hiroshi Komatsu, Hiroaki Tomita

    Frontiers in Psychiatry　2024年2月

  43. Effect of the guideline education program on anticholinergic and benzodiazepine use in outpatients with schizophrenia and major depressive disorder: The Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project 査読有り

    Hirotaka Yamagata, Yuko Fujii, Shinichiro Ochi, Tomoe Seki, Naomi Hasegawa, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Jun-ichi Iga, Kazuyoshi Ogasawara, Naoki Hashimoto, Hitoshi Iida, Kazutaka Ohi, Takashi Tsuboi, Shusuke Numata, Akitoyo Hishimoto, Masahide Usami, Eiichi Katsumoto, Hiroyuki Muraoka, Yoshikazu Takaesu, Tatsuya Nagasawa, Hiroshi Komatsu, Kenichiro Miura, Junya Matsumoto, Ken Inada, Shin Nakagawa, Ryota Hashimoto

    Psychiatry Research Communications　2024年1月

  44. Slower clozapine titration is associated with delayed onset of clozapine-induced fever among Japanese patients with schizophrenia 査読有り

    Yuki Kikuchi, Yuji Yada, Yuji Otsuka, Fumiaki Ito, Hiroaki Tanifuji, Hiroshi Komatsu, Hiroaki Tomita

    Schizophrenia　9　(1)　2023年11月20日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1038/s41537-023-00412-6 　

    eISSN：2754-6993

    詳細を見る 詳細を閉じる

    Abstract Clozapine-induced fever marks the beginning of its inflammatory and potentially life-threatening adverse effects, such as myocarditis. We retrospectively analyzed the correlation between clozapine titration rate and fever onset date in 254 Japanese patients, including 55 with treatment-resistant schizophrenia who developed clozapine-induced fever. Pearson’s product-moment correlation indicated a significant delay in the fever onset date with slower titration. Most fever onset cases occurred within 4 weeks, even with slow titration. Therefore, clinicians should remain vigilant in monitoring clozapine-induced fever within 4 weeks of clozapine initiation, regardless of the titration rate.

  45. Concomitant use of clozapine and suvorexant doubled clozapine plasma levels: A case report 査読有り

    Yuki Kikuchi, Toshihiro Sato, Keiichi Murakami, Tatsui Otsuka, Terufumi Machida, Keigo Yoshikawa, Yoshiaki Shiozawa, Hiroshi Komatsu, Masamitsu Maekawa, Nariyasu Mano, Hiroaki Tomita

    Journal of Clinical Psychopharmacology　2023年11月

  46. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study 査読有り

    Naomi Hasegawa, Yuka Yasuda, Norio Yasui-Furukori, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Yoshikazu Takaesu, Hitoshi Iida, Hiroyuki Muraoka, Fumitoshi Kodaka, Jun-ichi Iga, Naoki Hashimoto, Kazuyoshi Ogasawara, Kazutaka Ohi, Kentro, Fukumoto, Shusuke Numata, Takashi Tsuboi, Masahide Usami, Akitoyo Hishimoto, Ryuji Furihata, Taishiro Kishimoto, Toshinori Nakamura, Eiichi Katsumoto, Shinichiro Ochi, Tatsuya Nagasawa, Kiyokazu Atake, Chika Kubota, Hiroshi Komatsu, Hirotaka Yamagata, Kenta Ide, Masahiro Takeshima, Mikio Kido, Saya Kikuchi, Tsuyoshi Okada, Junya Matsumoto, Kenichiro Miura, Taichi Shimazu, Ken Inada, Koichiro Watanabe, Ryota Hashimoto

    Psychiatry and Clinical Neurosciences　2023年7月

  47. Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: A retrospective chart review of seven hospitals 査読有り

    Yuki Kikuchi, Hiroshi Komatsu, Yuji Otsuka, Fumiaki Ito, Nobuhisa Kanahara, Hiroaki Tanifuji, Hiroaki Tomita

    Schizophrenia Research　2023年6月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.schres.2023.06.003 　

    ISSN：0920-9964

  48. Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics 査読有り

    Toshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, Takashi Tsuboi, Jun-ichi Iga, Norio Yasui-Furukori, Naoki Yamada, Hikaru Hori, Hiroyuki Muraoka, Kazutaka Ohi, Kazuyoshi Ogasawara, Ochi Shinichiro, Masahiro Takeshima, Kayo Ichihashi, Kentaro Fukumoto, Hitoshi Iida, Hisashi Yamada, Ryuji Furihata, Manabu Makinodan, Yoshikazu Takaesu, Shusuke Numata, Hiroshi Komatsu, Akitoyo Hishimoto, Mikio Kido, Kiyokazu Atake, Hirotaka Yamagata, Saya Kikuchi, Naoki Hashimoto, Masahide Usami, Eiichi Katsumoto, Takeshi Asami, Chika Kubota, Junya Matsumoto, Kenichiro Miura, Yoji Hirano, Koichiro Watanabe, Ken Inada, Ryota Hashimoto

    Journal of Clinical Psychopharmacology　Publish Ahead of Print　(4)　365-368　2023年5月23日

    出版者・発行元： Ovid Technologies (Wolters Kluwer Health)

    DOI： 10.1097/jcp.0000000000001704 　

    ISSN：0271-0749

    eISSN：1533-712X

  49. Change of prescription for patients with schizophrenia or major depressive disorder during admission: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education psychiatric treatment project 国際誌 査読有り

    Naoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, Shuhei Ishikawa, Hikaru Hori, Hitoshi Iida, Kayo Ichihashi, Kenichiro Miura, Junya Matsumoto, Shusuke Numata, Fumitoshi Kodaka, Ryuji Furihata, Kazutaka Ohi, Kazuyoshi Ogasawar, Jun-ichi Iga, Hiroyuki Muraok, Hiroshi Komatsu, Masahiro Takeshim, Kiyokazu Atake, Mikio Kido, Toshinori Nakamur, Taishiro Kishimoto, Akitoyo Hishimoto, Toshiaki Onitsuk, Tsuyoshi Okad, Shinichiro Ochi, Tatsuya Nagasaw, Manabu Makinod, Hiroki Yamad, Takashi Tsuboi, Hisashi Yamad, Ken Inada, Koichiro Watanabe, Ryota Hashimoto

    BMC Psychiatry　23　(1)　473-473　2023年5月

    DOI： 10.1186/s12888-023-04908-4 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants in major depressive disorder) is common in Japan. Our goal is to align psychotropic prescription in Japan with international standards, while reducing the differences between facilities. To achieve this goal, we aimed to compare prescriptions at the time of hospital admission and discharge. METHODS: Data on prescriptions at admission and discharge from 2016 to 2020 were collected. We divided the patients into four groups: (1) mono_mono group, monotherapy of the main drug at admission and discharge; (2) mono_poly group, monotherapy at admission and polypharmacy at discharge; (3) poly_poly group, polypharmacy at admission and discharge; and (4) poly_mono group, polypharmacy at admission and monotherapy at discharge. We compared the changes in dosage and number of psychotropics among the four groups. RESULTS: For both schizophrenia and major depressive disorder, the patients who received monotherapy with the main drug at admission were likely to receive main drug monotherapy at discharge and vice versa. For schizophrenia, the polypharmacy was prescribed more often in the mono_poly group than that in the mono_mono group. The prescription was not changed at all for more than 10% of the patients. CONCLUSIONS: It is critical to avoid a polypharmacy regimen to ensure that guideline-compliant treatment is provided. We expect higher rates of monotherapy with the main drug after the EGUIDE lectures. TRIAL REGISTRATION: The study protocol was registered in the University Hospital Medical Information Network Registry (UMIN000022645).

  50. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project 国際誌 査読有り

    Yoshitaka Kyou, Norio Yasui-Furukori, Naomi Hasegawa, Kenta Ide, Kayo Ichihashi, Naoki Hashimoto, Hikaru Hori, Yoshihito Shimizu, Yayoi Imamura, Hiroyuki Muraoka, Hitoshi Iida, Kazutaka Ohi, Yuka Yasuda, Kazuyoshi Ogasawara, Shusuke Numata, Jun-ichi Iga, Takashi Tsuboi, Shinichiro Ochi, Fumitoshi Kodaka, Ryuji Furihata, Toshiaki Onitsuka, Manabu Makinodan, Hiroshi Komatsu, Masahiro Takeshima, Chika Kubota, Akitoyo Hishimoto, Kiyokazu Atake, Hirotaka Yamagata, Mikio Kido, Tatsuya Nagasawa, Masahide Usami, Taishiro Kishimoto, Saya Kikuchi, Junya Matsumoto, Kenichiro Miura, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Ryota Hahimoto

    Annals of General Psychiatry　21　(1)　52-52　2022年12月26日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1186/s12991-022-00429-8 　

    eISSN：1744-859X

    詳細を見る 詳細を閉じる

    Abstract Background Several guidelines recommend monotherapy in pharmacotherapy for schizophrenia and major depressive disorder. The content of regular prescriptions has been reported in several studies, but not enough research has been conducted on the content of pharmacotherapy, including pro re nata (PRN) medications. The purpose of this study was to evaluate the content of pharmacotherapy, including PRN medications, and to clarify the relationship with regular prescriptions. Methods We used data from the “Effectiveness of Guidelines for Dissemination And Education in psychiatric treatment” (EGUIDE) project to investigate the presence or absence of PRN psychotropic medications at discharge for each drug category. We compared the PRN psychotropic prescription ratio at discharge by diagnosis for each drug category. The antipsychotic monotherapy ratio and no prescription ratio of other psychotropics for schizophrenia at discharge and the antidepressant monotherapy ratio and no prescription ratio of other psychotropics for major depressive disorder at discharge were calculated for each regular prescription, including PRN psychotropic medications, as quality indicators (QIs). Spearman's rank correlation test was performed for QI values of regular prescriptions and the QI ratio between regular prescriptions and prescriptions including PRN medications for each diagnosis. Results The PRN psychotropic prescription ratio at discharge was 28.7% for schizophrenia and 30.4% for major depressive disorder, with no significant differences by diagnosis. The prescription ratios of PRN antipsychotic medications and PRN antiparkinsonian medications were significantly higher for schizophrenia. The prescription ratios of PRN anxiolytic and hypnotic and PRN antidepressant medications were significantly higher for patients with major depressive disorder. For both schizophrenia and major depressive disorder, the QI was lower for discharge prescriptions, including PRN medications, than for regular prescriptions. QI values for regular prescriptions and the QI ratio were positively correlated. Conclusions Considering PRN psychotropic medications, the monotherapy ratio and no prescription ratio of other psychotropics at discharge decreased in pharmacotherapy for schizophrenia and major depressive disorder. A higher ratio of monotherapy and no prescription of other psychotropics on regular prescriptions may result in less concomitant use of PRN psychotropic medications. Further studies are needed to optimize PRN psychotropic prescriptions.

  51. Satisfaction with Web-Based Courses on Clinical Practice Guidelines for Psychiatrists: Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' Project 国際誌 査読有り

    Hitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, Naomi Hasegawa, Shusuke Numata, Kazuyoshi Ogasawara, Kenichiro Miura, Junya Matsumoto, Hikaru Hori, Jun-ichi Iga, Kayo Ichihashi, Naoki Hashimoto, Hisashi Yamad, Kazutaka Ohi, Norio Yasui-Furukori, Kentaro Fukumoto, Takashi Tsuboi, Masahide Usami, Ryuji Furihata, Yoshikazu Takaesu, Akitoyo Hishimoto, Hiroyuki Muraoka, Eiichi Katsumoto, Tatsuya Nagasawa, Shinichiro Ochi, Hiroshi Komatsu, Saya Kikuchi, Masahiro Takeshima, Toshiaki Onitsuka, Shinichiro Tamai, Chika Kubota, Ken Inada, Koichiro Watanabe, Hiroaki Kawasaki, Ryota Hashimoto

    Neuropsychopharmacology Reports　43　(1)　23-32　2022年11月

    DOI： 10.1002/npr2.12300 　

    詳細を見る 詳細を閉じる

    To disseminate, educate, and validate psychiatric clinical practice guidelines, the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project was launched in 2016. In this study, we investigated whether the web-based courses offered by this project would be as effective as the face-to-face courses. We analyzed and compared survey answers about overall participant satisfaction with the course and answers regarding clinical knowledge of schizophrenia and major depressive disorder between 170 participants who took the web-based courses in 2020 and 689 participants who took the face-to-face courses from 2016 to 2019. The web-based course participants completed the survey questions about satisfaction with the web-based courses. The web-based courses were conducted using a combination of web services to make it as similar as possible to the face-to-face courses. The degree of satisfaction assessed by the general evaluation of the web-based courses was higher than what was expected from the face-to-face courses. The degree of satisfaction was similar for the courses on schizophrenia and major depressive disorder. In addition, there were no significant differences in overall satisfaction and clinical knowledge between web-based and face-to-face courses. In conclusion, the web-based courses on clinical practice guidelines provided by the EGUIDE project were rated as more satisfying than the face-to-face course that the participants expected to take and no differences in the effectiveness of either course. The results suggest that, after the COVID-19 pandemic, it would be possible to disseminate this educational material more widely by adopting web-based courses additionally face-to-face courses.

  52. Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia” 国際誌 査読有り

    Ken Inada, Kentaro Fukumoto, Naomi Hasegawa, Yuka Yasuda, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Hitoshi Iida, Kazutaka Ohi, Hiroyuki Muraoka, Fumitoshi Kodaka, Kenta Ide, Naoki Hashimoto, Jun‐ichi Iga, Kazuyoshi Ogasawara, Kiyokazu Atake, Yoshikazu Takaesu, Tatsuya Nagasawa, Hiroshi Komatsu, Tsuyoshi Okada, Ryuji Furihata, Mikio Kido, Saya Kikuchi, Chika Kubota, Manabu Makinodan, Shinichiro Ochi, Masahiro Takeshima, Hirotaka Yamagata, Junya Matsumoto, Kenichiro Miura, Masahide Usami, Taishiro Kishimoto, Toshiaki Onitsuka, Eiichi Katsumoto, Akitoyo Hishimoto, Shusuke Numata, Norio Yasui‐Furukori, Koichiro Watanabe, Ryota Hashimoto

    Neuropsychopharmacology Reports　42　(4)　502-509　2022年10月18日

    出版者・発行元： Wiley

    DOI： 10.1002/npr2.12293 　

    ISSN：2574-173X

    eISSN：2574-173X

    詳細を見る 詳細を閉じる

    AIMS: The Guidelines for the Pharmacotherapy of Schizophrenia were established to improve the quality of medical care, and the EGUIDE project was conducted to train clinicians on guideline usage. A quality indicator (QI) was established to measure the prevalence of the guidelines, and a survey was conducted, which revealed a gap between the guidelines and actual clinical practice (evidence-practice-gap). The purpose of this study was to develop an individual fitness score (IFS) formula that expresses the degree to which prescribers adhere to the Guidelines for Pharmacological Therapy of Schizophrenia in a simple manner, and to determine the validity of this formula from a survey of the prescriptions of the EGUIDE project participants'. METHODS: To establish appropriate scores, members discussed the proposed formula and then voted on them. The IFS formula developed was set up so that antipsychotic monotherapy would be given 100 points, with points deducted if concomitant or adjunctive antipsychotic medications were used, and a minimum score of 0. To validate this formula, prescriptions of hospitalized schizophrenic patients at admission and at discharge were scored and compared. RESULT: IFS points vary and ranged from 0 to100. The average pre-admission score for all subjects was 45.6, and the average score at discharge was 54, those were significantly higher during discharge. CONCLUSIONS: We developed an IFS formula, a tool to easily visualize the degree to which current prescriptions conform to the guidelines for the pharmacological treatment of schizophrenia.

  53. Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score‐matched analysis 査読有り

    Takashi Tsuboi, Yoshikazu Takaesu, Naomi Hasegawa, Shinichiro Ochi, Kentaro Fukumoto, Kazutaka Ohi, Hiroyuki Muraoka, Tsuyoshi Okada, Funitoshi Kodaka, Shun Igarashi, Hitoshi Iida, Hiroko Kashiwagi, Hikaru Hori, Kayo Ichihashi, Kazuyoshi Ogasawara, Naoki Hashimoto, Jun‐Ichi Iga, Toshinori Nakamura, Masahide Usami, Tatsuya Nagasawa, Mikio Kido, Hiroshi Komatsu, Hirotaka Yamagata, Kiyokazu Atake, Ryuji Furihata, Saya Kikuchi, Tadasu Horai, Masahiro Takeshima, Yoji Hirano, Manabu Makinodan, Junya Matsumoto, Kenichiro Miura, Akitoyo Hishimoto, Shusuke Numata, Hisashi Yamada, Norio Yasui‐Furukori, Ken Inada, Koichiro Watanabe, Ryota Hashimoto

    Psychiatry and Clinical Neurosciences　77　(1)　30-37　2022年10月10日

    出版者・発行元： Wiley

    DOI： 10.1111/pcn.13489 　

    ISSN：1323-1316

    eISSN：1440-1819

  54. Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia 国際誌 査読有り

    Tsuyoshi Okada, Hikaru Hori, Naomi Hasegawa, Atsunobu Murata, Yoshitaka Kyou, Fumitoshi Kodaka, Hitoshi Iida, Shinichiro Ochi, Yoshikazu Takaesu, Takashi Tsuboi, Jun-ichi Iga, Kayo Ichihashi, Hiroyuki Muraoka, Ryuji Furihata, Norio Yasui-Furukori, Masahide Usami, Toshiaki Onitsuka, Kazuyoshi Ogasawara, Hiromi Tagata, Masahiro Takeshima, Kazutaka Ohi, Shusuke Numata, Naoki Hashimoto, Hiroki Yamada, Manabu Makinodan, Hiroshi Komatsu, Akitoyo Hishimoto, Hirotaka Yamagata, Mikio Kido, Chika Kubota, Kiyokazu Atake, Hisashi Yamada, Tatsuya Nagasawa, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Shiro Suda, Ryota Hashimoto

    Journal of Clinical Psychopharmacology　Publish Ahead of Print　2022年10月4日

    出版者・発行元： Ovid Technologies (Wolters Kluwer Health)

    DOI： 10.1097/jcp.0000000000001604 　

    ISSN：0271-0749

    eISSN：1533-712X

  55. Development of an individual fitness score (IFS) for based on the depression treatment guidelines of in the Japanese Society of Mood Disorders 査読有り

    Kentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, Hiroyuki Muraoka, Hikaru Hori, Kayo Ichihashi, Yuka Yasuda, Hitoshi Iida, Kazutaka Ohi, Shinichiro Ochi, Kenta Ide, Naoki Hashimot, Masahide Usami, Toshinori Nakamura, Hiroshi Komatsu, Tsuyoshi Okada, Tatsuya Nagasawa, Ryuji Furihata, Kiyokazu Atake, Mikio Kido, Saya Kikuchi, Hirotka Yamagata, Taishiro Kishimoto, Manabu Makinodan, Tadasu Horai, Masahiro Takeshima, Chika Kubota, Takeshi Asami, Eiichi Katsumoto, Akitoyo Hishimoto, Toshiaki Onitsuka, Junya Matsumoto, Kenichiro Miura, Hisashi Yamada, Norio Yasui-Furukori, Koichiro Watanabe, Ken Inada, Kotaro Otsuka, Ryota Hashimota

    Neuropsychopharmacology Reports　2022年10月

  56. Successful rechallenge with clozapine after discontinuation due to drug‐induced pneumonia: A case report 査読有り

    Yuki Kikuchi, Hiroshi Komatsu, Atsushi Sakuma, Hiroaki Tanifuji, Hiroaki Tomita

    Psychiatry and Clinical Neurosciences Reports　1　(3)　2022年9月

    出版者・発行元： Wiley

    DOI： 10.1002/pcn5.38 　

    ISSN：2769-2558

    eISSN：2769-2558

  57. Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: A real-world nationwide study 国際誌 査読有り

    Shinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, Norio Yasui-Furukori, Jun-ichi Iga, Hiroko Kashiwagi, Fumitoshi Kodaka, Hiroshi Komatsu, Takashi Tsuboi, Akira Tokutani, Shusuke Numata, Kayo Ichihashi, Toshiaki Onitsuka, Hiroyuki Muraoka, Hitoshi Iida, Kazutaka Ohi, Kiyokazu Atake, Taishiro Kishimoto, Hikaru Hori, Yoshikazu Takaesu, Masahiro Takeshima, Masahide Usami, Manabu Makinodan, Naoki Hashimoto, Michiko Fujimoto, Ryuji Furihata, Tatsuya Nagasawa, Hisashi Yamada, Junya Matsumoto, Kenichiro Miura, Mikio Kido, Akitoyo Hishimoto, Shu-ichi Ueno, Koichiro Watanabe, Ken Inada, Ryota Hashimoto

    International Journal of Neuropsychopharmacology　25　(10)　818-826　2022年6月20日

    出版者・発行元： Oxford University Press (OUP)

    DOI： 10.1093/ijnp/pyac036 　

    ISSN：1461-1457

    eISSN：1469-5111

    詳細を見る 詳細を閉じる

    Abstract Background Although clozapine is effective for treatment-resistant schizophrenia (TRS), the rate of clozapine prescription is still low. Although antipsychotic monotherapy is recommended in clinical practice guidelines, the rate of antipsychotic polypharmacy is still high. There is little evidence on whether a clozapine prescription influences changes in the rate of monotherapy and polypharmacy, including antipsychotics and other psychotropics. We therefore hypothesized that the rate of antipsychotic monotherapy in patients with TRS who were prescribed clozapine would be higher than that in patients with schizophrenia who were not prescribed clozapine. Methods We assessed 8306 patients with schizophrenia nationwide from 178 institutions in Japan from 2016 to 2019. We analyzed the psychotropic prescription data at discharge in patients diagnosed with TRS and with no description of TRS (ND-TRS) based on the diagnosis listed in the discharge summary. Results The rate of antipsychotic monotherapy in the TRS with clozapine group (91.3%) was significantly higher than that in the TRS without clozapine group (45.9%; p &amp;lt; 2.0 × 10 -16) and the ND-TRS without clozapine group (54.7%; p &amp;lt; 2.0 × 10 -16). The rate of antipsychotic monotherapy without any other concomitant psychotropics in the TRS with clozapine group (26.5%) was significantly higher than that in the TRS without clozapine group (12.6%; p = 1.1 × 10 -6) and the ND-TRS without clozapine group (17.0%; p = 5.9 × 10 -6). Conclusions Clozapine prescription could be associated with a high rate of antipsychotic monotherapy. Patients will benefit from the correct diagnosis of TRS and thus from proper clozapine prescription.

  58. Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics 国際誌 査読有り

    Hikaru Hori, Norio Yasui-Furukori, Naomi Hasegawa, Jun-ichi Iga, Shinichiro Ochi, Kayo Ichihashi, Ryuji Furihata, Yoshitaka Kyo, Yoshikazu Takaesu, Takashi Tsuboi, Fumitoshi Kodaka, Toshiaki Onitsuka, Tsuyoshi Okada, Atsunobu Murata, Hiroko Kashiwagi, Hitoshi Iida, Naoki Hashimoto, Kazutaka Ohi, Hisashi Yamada, Kazuyoshi Ogasawara, Yuka Yasuda, Hiroyuki Muraoka, Masahide Usami, Shusuke Numata, Masahiro Takeshima, Hirotaka Yamagata, Tatsuya Nagasawa, Hiromi Tagata, Manabu Makinodan, Mikio Kido, Eiichi Katsumoto, Hiroshi Komatsu, Junya Matsumoto, Chika Kubota, Kenichiro Miura, Akitoyo Hishimoto, Koichiro Watanabe, Ken Inada, Hiroaki Kawasaki, Ryota Hashimoto

    Frontiers in Psychiatry　13　823826-823826　2022年5月17日

    出版者・発行元： Frontiers Media SA

    DOI： 10.3389/fpsyt.2022.823826 　

    eISSN：1664-0640

    詳細を見る 詳細を閉じる

    In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups—low rate group (LG), medium rate group (MG), and high rate group (HG)—according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.

  59. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study 国際誌 査読有り

    Hiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, Norio Yasui-Furukori, Kentaro Fukumoto, Hiroko Kashiwagi, Hiromi Tagata, Hikaru Hori, Kiyokazu Atake, Hitoshi Iida, Kayo Ichihashi, Ryuji Furihata, Takashi Tsuboi, Masahiro Takeshima, Hiroshi Komatsu, Chika Kubota, Shinichiro Ochi, Yoshikazu Takaesu, Masahide Usami, Tatsuya Nagasawa, Manabu Makinodan, Toshinori Nakamura, Mikio Kido, Ikki Ueda, Hirotaka Yamagata, Toshiaki Onitsuka, Takeshi Asami, Akitoyo Hishimoto, Kazuyoshi Ogasawara, Eiichi Katsumoto, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Katsuji Nishimura, Ryota Hashimoto

    Asian Journal of Psychiatry　74　103174-103174　2022年5月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.ajp.2022.103174 　

    ISSN：1876-2018

    詳細を見る 詳細を閉じる

    PURPOSE: In the treatment guidelines for major depressive disorder (MDD), the recommended treatment differs based on the severity. However, the type of treatment provided based on the severity of MDD in real-world clinical practice has not been investigated. In this study, we clarified the actual situation of MDD treatment in clinical practice and compared the treatment based on the severity of MDD. METHODS: We used data from 1484 patients with MDD at discharge from October 2016 to March 2020. RESULTS: The number of psychotropic prescriptions tended to be lower in those diagnosed with MDD in the severe group compared to in the non-severe group. There were significant differences among the three groups (mild, moderate/severe, and psychotic) in the percentage of patients who were not prescribed antipsychotics (p = 1.9 ×10-6), a combination of antipsychotics and antidepressants (p = 5.0 ×10-4), and the implementation rate of modified electroconvulsive therapy (m-ECT) (p = 3.4 ×10-9). The percentage of patients with a severe diagnosis who underwent m-ECT was higher, which corresponded to the severity. CONCLUSION: Our findings showed that the use of psychotropics decreased when the severity of MDD was diagnosed, and the rate of a combination of antipsychotics and antidepressants and the implementation rate of m-ECT increased with the severity. However, this study suggests that there is still an evidence-practice gap in the treatment of MDD in Japan, and guidelines are only partially adhered to in the treatment of depression.

  60. A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project 国際誌 査読有り

    Hisashi Yamada, Mikuni Motoyama, Naomi Hasegawa, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Norio Yasui-Furukori, Shusuke Numata, Masahiro Takeshima, Nobuhiro Sugiyama, Tatsuya Nagasawa, Chika Kubota, Kiyokazu Atake, Takashi Tsuboi, Kayo Ichihashi, Naoki Hashimoto, Takahiko Inagaki, Yoshikazu Takaesu, Jun-ichi Iga, Hikaru Hori, Toshiaki Onitsuka, Hiroshi Komatsu, Akitoyo Hishimoto, Kentaro Fukumoto, Michiko Fujimoto, Toshinori Nakamura, Kiyotaka Nemoto, Ryuji Furihata, Satoshi Yamamura, Hirotaka Yamagata, Kazuyoshi Ogasawara, Eiichi Katsumoto, Atsunobu Murata, Hitoshi Iida, Shinichiro Ochi, Manabu Makinodan, Mikio Kido, Taishiro Kishimoto, Yuka Yasuda, Masahide Usami, Taro Suwa, Ken Inada, Koichiro Watanabe, Ryota Hashimoto

    BJPsych Open　8　(3)　e83　2022年5月

    出版者・発行元： Royal College of Psychiatrists

    DOI： 10.1192/bjo.2022.44 　

    eISSN：2056-4724

    詳細を見る 詳細を閉じる

    Background Clinical practice guidelines for schizophrenia and major depressive disorder have been published. However, these have not had sufficient penetration in clinical settings. We developed the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project as a dissemination and education programme for psychiatrists. Aims The aim of this study is to assess the effectiveness of the EGUIDE project on the subjective clinical behaviour of psychiatrists in accordance with clinical practice guidelines before and 1 and 2 years after participation in the programmes. Method A total of 607 psychiatrists participated in this study during October 2016 and March 2019. They attended both 1-day educational programmes based on the clinical practice guidelines for schizophrenia and major depressive disorder, and answered web questionnaires about their clinical behaviours before and 1 and 2 years after attending the programmes. We evaluated the changes in clinical behaviours in accordance with the clinical practice guidelines between before and 2 years after the programme. Results All of the scores for clinical behaviours in accordance with clinical practice guidelines were significantly improved after 1 and 2 years compared with before attending the programmes. There were no significant changes in any of the scores between 1 and 2 years after attending. Conclusions All clinical behaviours in accordance with clinical practice guidelines improved after attending the EGUIDE programme, and were maintained for at least 2 years. The EGUIDE project could contribute to improved guideline-based clinical behaviour among psychiatrists.

  61. The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication 国際誌 査読有り

    Atsuhiro Miyazawa, Nobuhisa Kanahara, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Hiroshi Komatsu, Yuto Masumo, Yusuke Nakata, Masaomi Iyo

    Journal of Psychopharmacology　36　(4)　026988112210787-026988112210787　2022年4月27日

    出版者・発行元： SAGE Publications

    DOI： 10.1177/02698811221078751 　

    ISSN：0269-8811

    eISSN：1461-7285

    詳細を見る 詳細を閉じる

    Background: Although numerous studies reported some changes of cortical silent period (CSP), an indicator of gamma-aminobutyric acid (GABA) function in central nervous system, in schizophrenia patients, it has been unknown how the disease stage and antipsychotic medication affect CSP values. Methods: The present study conducted a systematic review of previous literature comparing CSP between schizophrenia patients and healthy subjects, and then performed meta-analysis on the effects of (1) the disease stage and (2) antipsychotics on CSP. Results: (1) In the comparison of the disease stage comprising a total of 17 reports, there was no significant difference in CSP between patients under drug-naïve first-episode psychoses and healthy controls, or between patients with antipsychotic medication and healthy controls. (2) In the comparison of the antipsychotic class, patients treated with clozapine were longer in CSP compared to healthy controls. Patients treated with olanzapine/quetiapine or with other type of antipsychotics were not different from healthy controls. Regarding other type of antipsychotics, the iteration analysis after leaving out one literature showed that patients were shorter in CSP than healthy controls. Conclusion: The results showed that clozapine seems to surely prolong CSP, indicating the enhancement of GABA transmission via GABAB receptors, suggesting the possible relationship between the CSP prolongation by clozapine and its high efficacy in psychopathology. The finding of shorter CSP in patients with other type of antipsychotics was distinct from clozapine/olanzapine/quetiapine, but was difficult to interpret since this group included a variety of transcranial magnetic stimulation (TMS) methodologies and patients’ background.

  62. Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry 国際誌 査読有り

    Kazuyoshi Ogasawara, Shusuke Numata, Naomi Hasegawa, Masahito Nakataki, Manabu Makinodan, Kazutaka Ohi, Masahiro Takeshima, Takashi Tsuboi, Naoki Hashimoto, Toshiaki Onitsuka, Hiroyuki Muraoka, Hikaru Hori, Kayo Ichihashi, Takahiko Inagaki, Norio Yasui‐Furukori, Akitoyo Hishimoto, Nobuhiro Sugiyama, Kentaro Fukumoto, Tatsuya Nagasawa, Junya Matsumoto, Yoshikazu Takaesu, Ryuji Furihata, Kiyotaka Nemoto, Toshinori Nakamura, Masahide Usami, Kenichiro Miura, Michiko Fujimoto, Hiromi Tagata, Hisashi Yamada, Hiroshi Komatsu, Shinichiro Ochi, Kiyokazu Atake, Eiichi Katsumoto, Mikio Kido, Taishiro Kishimoto, Taro Suwa, Satoshi Yamamura, Jun‐ichi Iga, Hitoshi Iida, Ken Inada, Koichiro Watanabe, Ryota Hashimoto

    Neuropsychopharmacology Reports　42　(2)　221-225　2022年3月10日

    出版者・発行元： Wiley

    DOI： 10.1002/npr2.12245 　

    ISSN：2574-173X

    eISSN：2574-173X

    詳細を見る 詳細を閉じる

    The Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) project, which is a nationwide dissemination and implementation program for clinical practice guidelines (CPGs) in the field of psychiatry, is currently ongoing. In the current study, a subjective assessment of the participants in the EGUIDE programs was assessed using a questionnaire. Then, the relationships between the subjective assessment, the characteristics of the participants, and the clinical knowledge of the CPGs were evaluated. More than 90% of the participants gave a high rating for the components of content, recommendation, knowledge, skill, and adherence, but not for the component of confidence. A positive correlation was found between years of professional experience and the score of confidence. These results suggest that it may be necessary to apply the knowledge and skills of CPGs obtained in the education programs into practice to increase confidence in the proper use of psychiatric therapies based on CPGs.

  63. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project 査読有り

    Kayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, Norio Yasui-Furukori, Yoshihito Shimizu, Hikaru Hori, Naoki Hashimoto, Kenta Ide, Yayoi Imamura, Hisashi Yamada, Shinichiro Ochi, Jun-ichi Iga, Yoshikazu Takaesu, Kazutaka Ohi, Takashi Tsuboi, Hitoshi Iida, Hirotaka Yamagata, Akitoyo Hishimoto, Tadasu Horai, Masahide Usami, Manabu Makinodan, Tatsuya Nagasawa, Hiroshi Komatsu, Mikio Kido, Hiroyuki Muraoka, Kiyokazu Atake, Masahiro Takeshima, Chika Kubota, Takahiko Inagaki, Shinichiro Tamai, Taishiro Kishimoto, Ryuji Furihata, Junya Matsumoto, Kenichiro Miura, Ken Inada, Koichiro Watanabe, Kiyoto Kasai, Ryota Hashimoto

    Asian Journal of Psychiatry　69　103007-103007　2022年3月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.ajp.2022.103007 　

    ISSN：1876-2018

    eISSN：1876-2026

  64. Deficient Autophagy in Microglia Aggravates Repeated Social Defeat Stress-Induced Social Avoidance 国際誌 査読有り

    Mai Sakai, Zhiqian Yu, Ryo Hirayama, Masa Nakasato, Yoshie Kikuchi, Chiaki Ono, Hiroshi Komatsu, Miharu Nakanishi, Hatsumi Yoshii, David Stellwagen, Tomoyuki Furuyashiki, Masaaki Komatsu, Hiroaki Tomita

    Neural Plasticity　2022　1-13　2022年2月16日

    出版者・発行元： Hindawi Limited

    DOI： 10.1155/2022/7503553 　

    ISSN：2090-5904

    eISSN：1687-5443

    詳細を見る 詳細を閉じる

    Major depressive disorder (MDD) is associated with repeated exposure to environmental stress. Autophagy is activated under various stress conditions that are associated with several diseases in the brain. This study was aimed at elucidating the autophagy signaling changes in the prefrontal cortex (PFC) under repeated social defeat (RSD) to investigate the involvement of microglial autophagy in RSD-induced behavioral changes. We found that RSD stress, an animal model of MDD, significantly induced initial autophagic signals followed by increased transcription of autophagy-related genes (Atg6, Atg7, and Atg12) in the PFC. Similarly, significantly increased transcripts of ATGs (Atg6, Atg7, Atg12, and Atg5) were confirmed in the postmortem PFC of patients with MDD. The protein levels of the prefrontal cortical LC3B were significantly increased, whereas p62 was significantly decreased in the resilient but not in susceptible mice and patients with MDD. This indicates that enhanced autophagic flux may alleviate stress-induced depression. Furthermore, we identified that FKBP5, an early-stage autophagy regulator, was significantly increased in the PFC of resilient mice at the transcript and protein levels. In addition, the resilient mice exhibited enhanced autophagic flux in the prefrontal cortical microglia, and the autophagic deficiency in microglia aggravated RSD-induced social avoidance, indicating that microglial autophagy involves stress-induced behavioral changes.

  65. Hypotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study 国際誌 査読有り

    Ryuji Furihata, Rei Otsuki, Naomi Hasegawa, Takashi Tsuboi, Shusuke Numata, Norio Yasui-Furukori, Hiroko Kashiwagi, Hikaru Hori, Shinichiro Ochi, Hiroyuki Muraoka, Toshiaki Onitsuka, Hiroshi Komatsu, Masahiro Takeshima, Akitoyo Hishimoto, Tatsuya Nagasawa, Yoshikazu Takaesu, Toshinori Nakamura, Takeshi Asami, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Yuka Yasuda, Hitoshi Iida, Kazuyoshi Ogasawara, Naoki Hashimoto, Kayo Ichihashi, Hisashi Yamada, Koichiro Watanabe, Ken Inada, Ryota Hashimoto

    Sleep Medicine　89　23-30　2022年1月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.sleep.2021.11.005 　

    ISSN：1389-9457

    詳細を見る 詳細を閉じる

    STUDY OBJECTIVES: To investigate the proportion of inpatients with schizophrenia and major depressive disorder prescribed hypnotic medication, and the association between such medication and the use of other antipsychotic agents. METHODS: This was a nationwide cross-sectional study performed as part of the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment' (EGUIDE) project. Data from 2146 inpatients with schizophrenia and 1031 inpatients with major depressive disorder were analyzed. All types and dosages of psychotropic drugs were recorded and the data at the time of discharge were analyzed. Associations between the use of hypnotic medication and other antipsychotic agents were evaluated using multivariate logistic regression analyses. RESULTS: The proportions of schizophrenia patients who were prescribed any and two or more hypnotic agents were 55.7% and 17.6%, respectively, and the corresponding proportions for patients with major depressive disorder were 63.6% and 22.6%, respectively. In schizophrenia patients, multivariate logistic regression analyses showed that two or more antipsychotics, anticholinergic drugs, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. In patients with major depressive disorder, multivariate logistic regression analyses revealed that two or more antidepressants, two or more antipsychotics, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. CONCLUSIONS: Prescription of hypnotic agents was found to be highly frequent among inpatients with psychiatric disorders. Prescription of two or more main antipsychotic agents was commonly associated with the use of hypnotic medication for both schizophrenia and major depressive disorder.

  66. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project 国際誌 査読有り

    Naoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, Shuhei Ishikawa, Shusuke Numata, Hikaru Hori, Hitoshi Iida, Kayo Ichihashi, Ryuji Furihata, Atsunobu Murata, Takashi Tsuboi, Masahiro Takeshima, Yoshitaka Kyou, Hiroshi Komatsu, Chika Kubota, Shinichiro Ochi, Yoshikazu Takaesu, Masahide Usami, Tatsuya Nagasawa, Akitoyo Hishimoto, Kenichiro Miura, Junya Matsumoto, Kazutaka Ohi, Hisashi Yamada, Ken Inada, Koichiro Watanabe, Kazutaka Shimoda, Ryota Hashimoto

    Asian Journal of Psychiatry　63　102744-102744　2021年7月

    出版者・発行元： Elsevier BV

    DOI： 10.1016/j.ajp.2021.102744 　

    ISSN：1876-2018

    詳細を見る 詳細を閉じる

    BACKGROUND: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists. METHODS: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. RESULTS: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. CONCLUSIONS: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction.

  67. Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. 国際誌 査読有り

    Hitoshi Iida, Junichi Iga, Naomi Hasegawa, Yuka Yasuda, Tomoya Yamamoto, Kenichiro Miura, Junya Matsumoto, Atsunobu Murata, Kazuyoshi Ogasawara, Hisashi Yamada, Hikaru Hori, Kayo Ichihashi, Naoki Hashimoto, Kazutaka Ohi, Norio Yasui-Furukori, Takashi Tsuboi, Toshinori Nakamura, Masahide Usami, Ryuji Furihata, Yoshikazu Takaesu, Kunihiro Iwamoto, Nobuhiro Sugiyama, Taishiro Kishimoto, Naohisa Tsujino, Hiroki Yamada, Akitoyo Hishimoto, Kiyotaka Nemoto, Kiyokazu Atake, Hiroyuki Muraoka, Eiichi Katsumoto, Satoru Oishi, Takahiko Inagaki, Fumiaki Ito, Yayoi Imamura, Mikio Kido, Tatsuya Nagasawa, Shusuke Numata, Shinichiro Ochi, Masaaki Iwata, Hidenaga Yamamori, Junichi Fujita, Toshiaki Onitsuka, Satoshi Yamamura, Manabu Makinodan, Michiko Fujimoto, Yoichiro Takayanagi, Kenji Takezawa, Hiroshi Komatsu, Kentaro Fukumoto, Shinichiro Tamai, Hirotaka Yamagata, Chika Kubota, Tadasu Horai, Ken Inada, Koichiro Watanabe, Hiroaki Kawasaki, Ryota Hashimoto

    Psychiatry and clinical neurosciences　74　(12)　667-669　2020年12月

    DOI： 10.1111/pcn.13143 　

  68. 【向精神薬の多剤規制と減量・離脱の実際】多剤大量療法の統合失調症患者におけるSCAP法半量以下での抗精神病薬減薬の試み 査読有り

    石田 雄介, 小松 浩, 佐藤 貴子, 名村 真由美, 安達 健朗, 槙 貴浩, 高橋 恵美, 三嶋 洋一, 岡嶋 みどり, 角藤 芳久

    臨床精神薬理　20　(9)　1057-1067　2017年9月

    出版者・発行元： (株)星和書店

    ISSN：1343-3474

  69. Four mood stabilizers commonly induce FEZ1 expression in human astrocytes 査読有り

    Zhiqian Yu, Chiaki Ono, Helen B Kim, Hiroshi Komatsu, Yoichiro Tanabe, Nobutaka Sakae, Keiichi I Nakayama, Hiroo Matsuoka, Ichiro Sora, William E Bunney, Hiroaki Tomita

    Bipolar Disorders　13　(5-6)　486-499　2011年8月

    出版者・発行元： Wiley

    DOI： 10.1111/j.1399-5618.2011.00946.x 　

    ISSN：1398-5647

  70. The involvement of micro-opioid receptors in the central nervous system in the worsening of allergic airway inflammation by psychological stress in mice. 国際誌 査読有り

    Kaori Okuyama, Kana Wada, Shinobu Sakurada, Hirokazu Mizoguchi, Hiroshi Komatsu, Ichiro Sora, Gen Tamura, Yuichi Ohkawara, Motoaki Takayanagi, Isao Ohno

    International archives of allergy and immunology　152　(4)　342-52　2010年

    DOI： 10.1159/000288287 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Psychological stress has a recognized association with asthma symptoms. However, the mechanisms linking stress to the exacerbation of asthma are not well defined. mu-Opioid receptors (MOR) have been shown to be involved in the shift of the immune system toward a Th2-predominant response caused by psychological stress. OBJECTIVE: To test the hypothesis that MOR play a role in the worsening of allergic airway inflammation evoked by psychological stress. METHODS: Sensitized mice were exposed to restraint stress followed by antigen challenge. The levels of corticosterone and ovalbumin (OVA)-specific IgE in the blood and the levels of inflammatory cells and cytokine contents in bronchoalveolar lavage fluid were compared between stressed and nonstressed mice. The effects of MOR gene deletion and MOR antagonists/agonists were also investigated. RESULTS: Stress exposure was confirmed by an increase in corticosterone levels. Although OVA-specific IgE levels were not significantly different, the numbers of inflammatory cells and Th2 cytokine levels after antigen challenge in stressed mice were significantly higher than in nonstressed mice. MOR gene deletion ameliorated the stress-induced worsening of antigen-induced airway inflammation, and the administration of morphine, a MOR agonist, reproduced the stress-induced antigen-induced airway inflammation. Selective blocking of MOR in the central nervous system (CNS) significantly reduced stress-induced inflammatory exacerbation, but the blocking of peripheral MOR did not. CONCLUSIONS: MOR in the CNS are involved in psychological stress-induced aggravation of allergic airway inflammation.

  71. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. 国際誌 査読有り

    Kenichi Fukuda, Masakazu Hayashida, Soichiro Ide, Naoko Saita, Yoshihiko Kokita, Shinya Kasai, Daisuke Nishizawa, Yasukazu Ogai, Junko Hasegawa, Makoto Nagashima, Megumi Tagami, Hiroshi Komatsu, Ichiro Sora, Hisashi Koga, Yuzuru Kaneko, Kazutaka Ikeda

    Pain　147　(1-3)　194-201　2009年12月15日

    DOI： 10.1016/j.pain.2009.09.004 　

    詳細を見る 詳細を閉じる

    Individual differences in sensitivity to fentanyl, a widely used opioid analgesic, can hamper effective pain treatment. Still controversial is whether the single nucleotide polymorphisms (SNPs) of the human OPRM1 gene encoding the mu-opioid receptor influence the analgesic effects of opioids. We examined associations between fentanyl sensitivity and the two SNPs, A118G and IVS3+A8449G, in the human OPRM1 gene in 280 Japanese patients undergoing painful orofacial cosmetic surgery, including bone dissection. Regarding the A118G SNP in exon 1, in a cold pressor-induced pain test before surgery, less analgesic effects of fentanyl were shown in subjects carrying the minor G allele of the A118G SNP (median of difference between pain perception latencies before and after fentanyl injection [PPLpost-PPLpre]: 12s) compared with subjects not carrying this allele (PPLpost-PPLpre: 15s, p=0.046). Furthermore, the IVS3+A8449G SNP in intron 3, which represents a complete linkage disequilibrium block with more than 30 SNPs from intron 3 to the 3' untranslated region, was associated with 24-h postoperative fentanyl requirements. Subjects carrying the minor G allele of the IVS3+A8449G SNP required significantly less fentanyl for 24-h postoperative pain control (median: 1.5microg/kg) compared with subjects not carrying this allele (median: 2.5microg/kg, p=0.010). Although further validation is needed, the present findings shed light on the involvement of OPRM1 3' untranslated region polymorphisms in fentanyl sensitivity in addition to the A118G SNP and open new avenues for personalized pain treatment with fentanyl.

  72. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. 国際誌 査読有り

    Masakazu Hayashida, Makoto Nagashima, Yasuo Satoh, Ryoji Katoh, Megumi Tagami, Soichiro Ide, Shinya Kasai, Daisuke Nishizawa, Yasukazu Ogai, Junko Hasegawa, Hiroshi Komatsu, Ichiro Sora, Kenichi Fukuda, Hisashi Koga, Kazuo Hanaoka, Kazutaka Ikeda

    Pharmacogenomics　9　(11)　1605-16　2008年11月

    DOI： 10.2217/14622416.9.11.1605 　

    詳細を見る 詳細を閉じる

    AIMS: The association between SNPs of the human OPRM1 gene encoding the micro-opioid receptor and postoperative analgesic requirements in surgical patients remains controversial. Here, we evaluate whether any of the five tag SNPs (A118G, IVS2+G691C, IVS3+G5953A, IVS3+A8449G and TAA+A2109G) representing the four linkage disequilibrium blocks of the OPRM1 gene influences postoperative analgesic requirements. MATERIALS & METHODS: We studied 138 adult Japanese patients who underwent major open abdominal surgery under combined general and epidural anesthesia and received continuous postoperative epidural analgesia with opioids. RESULTS: The 118G homozygous (GG) patients required 24-h postoperative analgesics more than 118A homozygous (AA) and heterozygous (AG) patients. Tag SNP haplotypes also were associated with 24-h postoperative analgesic requirements. CONCLUSIONS: These results suggest that OPRM1 gene tag SNP genotypes and haplotypes can primarily contribute to prediction of postoperative analgesic requirements in individual patients undergoing major open abdominal surgery.

  73. インターネットを用いた未規制薬物乱用の実態調査 査読有り

    小原 可久, 沼知 陽太郎, 小林 秀昭, 山下 元康, 渡邉 秀和, 福島 攝, 小松 浩, 畑 春美, 仲 真樹, 近江 香予, 曽良 一郎

    日本神経精神薬理学雑誌　24　(5)　316-318　2004年10月

    出版者・発行元： (一社)日本神経精神薬理学会

    ISSN：1340-2544

    詳細を見る 詳細を閉じる

    未規制薬物乱用の全体像を把握するため,インターネットによる情報流通の密度等から,乱用の実態の推測を試みた.その結果,法的な規制/未規制というのは,薬物毒性の低度を直接的に反映しておらず,未規制でも使用者人口がそれなりに存在しながら,具体的な研究がなされておらず,薬物毒性に対する被害が推測されながら実際には確認されていない物質が多々見受けられた.このような未規制薬物の薬理学的解析モデルを動物等を利用して,精神・神経毒性を明らかにする研究の推進が急務である.さらに研究推進により得られた未規制薬物の精神・神経毒性に関する正確な知識の啓蒙も必要と考えられた

︎全件表示 ︎最初の5件までを表示

MISC 76

  1. 精神科診療における緑内障患者への向精神薬使用の注意点 招待有り

    小松浩, 曽良かおり, 塩澤慶明, 山内昂也, 内海裕介, 小野口豪

    臨床精神薬理　第29巻　(08号)　2026年7月

  2. 統合失調症と緑内障における網膜菲薄化・血管病態機序の異同解明を通した診療技術開発

    小松浩

    先進医薬研究振興財団研究成果報告集　2025　2026年

    ISSN： 2189-1303

  3. A RETROSPECTIVE COMPARATIVE STUDY OF CLINICAL RESPONSE TO CLOZAPINE BETWEEN PATIENTS WITH EARLY TREATMENT-RESISTANT SCHIZOPHRENIA (TRS) AND LATE TRS

    Nobuhisa Kanahara, Kazuki Okada, Yuji Otsuka, Remiko Kobayashi, Hiroshi Kimura, Hiroshi Yamanaka, Yuri Takaoki, Taisuke Yoshida, Takahiro Oiwa, Fumiaki Ito, Hiroshi Komatsu, Takashi Ono, Yuki Kikuchi, Takahisa Saiga, Shingo Noda, Masaomi Iyo

    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY　28　i354-i355　2025年2月12日

    DOI： 10.1093/ijnp/pyae059.629 　

    ISSN： 1461-1457

    eISSN： 1469-5111

  4. 治療抵抗性統合失調症患者のクロザピン血中動態変動へのOATP1B1の影響

    佐藤紀宏, 川端猛, 公文代將希, 林和未, 小松浩, 菊地佑樹, 小野口豪, 小野口豪, 佐藤裕, 七谷圭, 七谷圭, 平塚真弘, 平塚真弘, 平塚真弘, 平塚真弘, 前川正充, 前川正充, 前川正充, 山口浩明, 山口浩明, 阿部高明, 阿部高明, 富田博秋, 富田博秋, 眞野成康, 眞野成康

    臨床薬理の進歩　(46)　2025年

    ISSN： 0914-4366

  5. クロザピン抵抗性統合失調症に対して急性期電気けいれん療法を施行した1例

    吉川佳吾, 山内昂也, 小松浩, 佐久間篤, 富田博秋, 富田博秋

    精神神経学雑誌　127　(5)　2025年

    ISSN： 0033-2658

  6. 双極性障害におけるADHD特性と認知機能の直接的または抑うつ症状とレジリエンス経由での社会機能への影響

    小野口 豪, 小松 浩, 割田 紀子, 小野 千晶, 堀越 翔, 富田 博秋

    精神神経学雑誌　(2024特別号)　S397-S397　2024年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  7. 光干渉断層計による統合失調症の網膜厚および血管密度の解析研究 潜在的バイオマーカーとしての網膜

    小松 浩, 小野口 豪, 矢花 武史, 佐熊 惇, 宮 武博, 中澤 徹, 富田 博秋

    精神神経学雑誌　(2024特別号)　S560-S560　2024年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  8. 治療抵抗性統合失調症早発型・後発型とクロザピン反応性 多施設共同後方視研究

    岡田 和樹, 金原 信久, 大塚 祐司, 山中 浩嗣, 齋賀 孝久, 高沖 侑里, 伊藤 文晃, 木村 大, 小松 浩, 吉田 泰介, 菊地 佑樹, 大岩 宜博, 大野 高志, 小林 玲美子, 伊豫 雅臣

    精神神経学雑誌　(2024特別号)　S654-S654　2024年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  9. 統合失調症スペクトラム患者における抗精神病薬の海馬体積に与える影響:系統的文献検索とメタ解析

    金原信久, 木村大, 小松浩, 伊豫雅臣, 伊豫雅臣

    日本脳科学会プログラム・講演抄録集　51st　2024年

  10. クロザピン処方可否と治療抵抗性統合失調症診断の有無が抗精神病薬単剤療法率に及ぼす影響に関する研究

    越智紳一郎, 小高文聰, 長谷川尚美, 伊賀淳一, 柏木宏子, 小松浩, 田形弘実, 坪井貴嗣, 沼田周助, 飯田仁志, 五十嵐俊, 大井一高, 福本健太郎, 村岡寛之, 松本純弥, 三浦健一郎, 上野修一, 渡邊衡一郎, 稲田健, 橋本亮太, 古郡規雄

    統合失調症研究(CD-ROM)　13　(1)　2024年

  11. 日本人のための,より安全なクロザピン導入プロトコルの検討

    菊地佑樹, 菊地佑樹, 小松浩, 富田博秋

    統合失調症研究(CD-ROM)　13　(1)　2024年

  12. クロザピンの血中濃度変動における有機アニオン輸送ポリペプチドの関与

    佐藤紀宏, 公文代將希, 林和未, 小野口豪, 小松浩, 平塚真弘, 平塚真弘, 前川正充, 前川正充, 富田博秋, 眞野成康, 眞野成康

    臨床化学(Web)　53　2024年

    ISSN： 0370-5633

  13. 幻覚妄想状態を呈し措置入院となったことを機に遺伝性脊髄小脳変性症の診断に至った1例

    村上桂一, 村上桂一, 小松浩, 大塚達以, 富田博秋

    精神神経学雑誌　126　(6)　2024年

    ISSN： 0033-2658

  14. クロザピン血中濃度変動と薬物動態関連因子の一塩基多型の関連解析

    佐藤 紀宏, 公文代 將希, 林 和未, 小野口 豪, 小松 浩, 平塚 真弘, 前川 正充, 富田 博秋, 眞野 成康

    日本臨床薬理学会学術総会抄録集　44回　1-5　2024年1月

    出版者・発行元： (一社)日本臨床薬理学会

    eISSN： 2436-5580

  15. 統合失調症と性差──なぜ男性の病理は重いのか

    兪志前, 小松浩, 富田博秋

    精神医学　66　(1)　81-87　2024年1月

  16. 東北大学病院精神科を拠点としたクロザピン療法,ECT,rTMS療法の地域連携体制の構築

    小松 浩, 小野口 豪, 富田 博秋

    総合病院精神医学　35　(Suppl.)　S-155　2023年11月

    出版者・発行元： (一社)日本総合病院精神医学会

    ISSN： 0915-5872

  17. 自殺企図を契機にレビー小体型認知症が疑われECTを施行した双極性障害の1例

    佐々木 茜, 高柳 義哉, 小番 健矢, 冨本 和歩, 佐久間 篤, 菊地 紗耶, 小松 浩, 富田 博秋

    総合病院精神医学　35　(Suppl.)　S-252　2023年11月

    出版者・発行元： (一社)日本総合病院精神医学会

    ISSN： 0915-5872

  18. 薬剤性イレウスをきたした治療抵抗性双極I型障害に対し維持ECTが有効であった一例

    小番 健矢, 小松 浩, 小林 奈津子, 冨本 和歩, 佐久間 篤, 富田 博秋

    総合病院精神医学　35　(Suppl.)　S-254　2023年11月

    出版者・発行元： (一社)日本総合病院精神医学会

    ISSN： 0915-5872

  19. 長期入院中の統合失調症患者のself-stigmaに関わる臨床要因に関する予備的検討

    尾之内 勇治, 小松 浩, 大野 高志, 富田 博秋, 角藤 芳久

    精神神経学雑誌　(2023特別号)　S395-S395　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  20. 統合失調症スペクトラム障害における網膜異常と精神症状の重症度との関連性 メタ解析による知見

    小松 浩, 小野口 豪, 矢花 武史, 富田 博秋

    精神神経学雑誌　(2023特別号)　S405-S405　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  21. クロザピン誘発性の薬剤性肺炎による投与中止後に、緩徐増量によりクロザピン再投与に成功した一例

    菊地 佑樹, 小松 浩, 佐久間 篤, 谷藤 弘淳, 富田 博秋

    精神神経学雑誌　(2023特別号)　S410-S410　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  22. New long-stay患者における自閉性特性と多飲症との関連についての調査

    小松 浩, 大野 高志, 尾之内 勇治, 小野口 豪, 米田 芳則, 富田 博秋, 角藤 芳久

    精神神経学雑誌　(2023特別号)　S580-S580　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  23. 統合失調症における自閉性と自閉スペクトラム症-病態における同異の研究を臨床に活かす知見- 統合失調症の自閉症的特性に関連するバイオマーカー研究の取り組み

    小松 浩, 小野口 豪, 富田 博秋

    精神神経学雑誌　(2023特別号)　S624-S624　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  24. 持続性抗精神病注射薬剤(LAI)と経口抗精神病薬の併用薬の状況 日本における実態調査

    鬼塚 俊明, 岡田 剛史, 長谷川 尚美, 坪井 貴嗣, 伊賀 淳一, 古郡 規雄, 山田 直輝, 堀 輝, 村岡 寛之, 大井 一高, 小笠原 一能, 越智 紳一郎, 竹島 正浩, 市橋 香代, 福本 健太郎, 飯田 仁志, 山田 恒, 降籏 隆二, 牧之段 学, 高江洲 義和, 沼田 周助, 小松 浩, 菱本 明豊, 木戸 幹雄, 阿竹 聖和, 山形 弘隆, 菊地 紗耶, 橋本 直樹, 宇佐美 政英, 勝元 榮一, 浅見 剛, 久保田 智香, 松本 純弥, 三浦 健一郎, 平野 羊嗣, 渡邊 衡一郎, 稲田 健, 橋本 亮太

    精神神経学雑誌　(2023特別号)　S684-S684　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  25. クロザピンが処方可能な施設体制と治療抵抗性の検討が統合失調症の抗精神病薬単剤治療に関連する

    越智 紳一郎, 小高 文聰, 長谷川 尚美, 古郡 規雄, 伊賀 淳一, 柏木 宏子, 小松 浩, 田形 弘実, 坪井 貴嗣, 沼田 周助, 飯田 仁志, 五十嵐 俊, 大井 一高, 高江洲 義和, 福本 健太郎, 村岡 寛之, 三浦 健一郎, 松本 純弥, 上野 修一, 渡邊 衡一郎, 稲田 健, 橋本 亮太

    精神神経学雑誌　(2023特別号)　S694-S694　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  26. 白血球数4000/μL未満による頻回の血液検査が続きクロザピン中止を希望した治療抵抗性統合失調症の一例

    佐久間 篤, 五十嵐 江美, 内海 裕介, 菊地 佑樹, 畠山 拓志, 高橋 雄太, 小松 浩, 菊地 紗耶, 富田 博秋

    精神神経学雑誌　(2023特別号)　S695-S695　2023年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  27. 私の研究生活の軌跡：大学院から臨床へ，そして再び研究の道へ

    小松 浩

    日本生物学的精神医学会誌　34　(3)　125-126　2023年

    出版者・発行元： 日本生物学的精神医学会

    DOI： 10.11249/jsbpjjpp.34.3_125 　

    ISSN： 2186-6619

    eISSN： 2186-6465

  28. 統合失調症患者のレジリエンスとセルフスティグマに焦点を当てた心理教育の可能性:予備的検討

    金原信久, 小林玲美子, 小松浩, 伊豫雅臣

    日本精神保健・予防学会学術集会プログラム・抄録集　26th　2023年

  29. 双極性障害患者におけるスーパー救急病棟入院後の簡易型集団心理教育参加後のself-stigmaの変化

    小松 浩, 大野 高志, 高梨 央康, 酒井 道代, 芳野 昭文, 岡村 知保, 石黒 奈々子, 伊木 威和, 菅原 聡美, 小野口 豪, 富田 博秋, 角藤 芳久

    日本精神科救急学会学術総会プログラム・抄録集　30回　140-140　2022年9月

    出版者・発行元： (一社)日本精神科救急学会

  30. 【よく目にする向精神薬の副作用への対処法】クロザピンによる顆粒球減少

    小野口 豪, 小松 浩, 富田 博秋

    精神科　41　(3)　1-5　2022年9月

  31. 双極性障害の集団心理教育参加後のself-stigmaの変化と心理教育の満足度、心理状態の変化との関連

    小松 浩, 大野 高志, 高梨 央康, 酒井 道代, 芳野 昭文, 岩崎 辰也, 笠原 猛, 岡村 知保, 石黒 奈々子, 伊木 威和, 菅原 聡美, 小野口 豪, 富田 博秋, 角藤 芳久

    精神神経学雑誌　124　(4付録)　S-367　2022年4月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  32. 治療抵抗性統合失調症の分類と治療 治療抵抗性統合失調症のサブタイプに基づく新規バイオマーカー同定と病態解明に向けた東北大学の取り組み

    小松 浩, 小野口 豪, 富田 博秋

    精神神経学雑誌　124　(4付録)　S-478　2022年4月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  33. 統合失調症スペクトラム障害における網膜層異常と臨床要因との関連性 系統的レビューとメタ解析

    小松 浩, 小野口 豪, Jerotic Stefan, 金原 信久, 角藤 芳久, 大野 高志, 舩越 俊一, 矢花 武史, 中澤 徹, 富田 博秋

    精神神経学雑誌　124　(4付録)　S-546　2022年4月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  34. スーパー救急病棟における双極性障害に対する集団心理教育の取り組み

    芳野昭文, 小松浩, 高梨央康, 酒井道代, 大野高志, 角藤芳久

    精神科看護　48　(2)　2021年11月

  35. New long stay患者の包括的な退院困難要因に関する調査 予備的検討

    小松 浩, 大野 高志, 米田 芳則, 石田 雄介, 槙 貴浩, 大場 綾希子, 鈴木 明, 森 康子, 庄司 盟子, 坂本 洋生, 尾崎 伸也, 海老名 貴幸, 高橋 幸子, 本間 竜太, 富田 博秋, 角藤 芳久

    精神神経学雑誌　(2021特別号)　S570-S570　2021年9月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  36. 鑑別に苦慮した老年期精神障害の3例

    小野口 豪, 小松 浩, 橘高 一, 富田 博秋

    精神神経学雑誌　123　(6)　367-367　2021年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  37. レビー小体型認知症と症候性てんかんによる意識障害が重畳していたと考えられる症例

    山内 昂也, 佐久間 篤, 田坂 有香, 小松 浩, 富田 博秋

    精神神経学雑誌　123　(6)　371-371　2021年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  38. 【夜間休日の措置入院に関する諸問題】宮城県立精神医療センターにおける夜間・休日の措置入院

    大野 高志, 小松 浩, 角藤 芳久

    精神科救急　23　20-23　2020年9月

    出版者・発行元： (一社)日本精神科救急学会

    ISSN： 1345-7837

  39. 統合失調症における自閉スペクトラム症傾向とリカバリーとの関係におけるself-stigmaと抑うつの媒介効果

    小松浩, 大野高志, 米田芳則, 藤田亨, 鈴木由美子, 菅原惣治, 角藤芳久

    日本精神神経学会総会プログラム・抄録集　116th　2020年

  40. 「重度かつ慢性」の基準案を満たす患者と満たさない長期入院患者のself-stigmaと認知機能障害に関する研究

    小松浩, 大野高志, 米田芳則, 石田雄介, 槙貴浩, 長谷諭, 大場綾希子, 手代木理, 鈴木明, 森康子, 庄司盟子, 藤田亨, 五十嵐佳代子, 坂本洋生, 尾崎伸也, 本間竜太, 角藤芳久

    日本精神神経学会総会プログラム・抄録集　116th　2020年

  41. 当院における持効性注射剤の使用実績と再入院予防効果の検討

    石田 雄介, 小松 浩, 秋葉 大輔, 岡村 知保, 小幡 拓也, 大野 高志, 角藤 芳久

    日本精神科救急学会学術総会プログラム・抄録集　27回　142-142　2019年10月

    出版者・発行元： (一社)日本精神科救急学会

  42. スーパー救急病棟入院中の統合失調症患者のセルフスティグマ、抑うつ症状、自閉スペクトラム症傾向、リカバリーとの関連について 外来患者との比較

    小松 浩, 大野 高志, 畠山 留美, 藤田 享, 米田 芳則, 本間 竜太, 鈴木 由美子, 菅原 惣治, 角藤 芳久

    日本精神科救急学会学術総会プログラム・抄録集　27回　168-168　2019年10月

    出版者・発行元： (一社)日本精神科救急学会

  43. 精神科救急病棟における双極性障害患者に対する簡易型集団心理教育の試みと有効性に関する予備的検討

    芳野 昭文, 小松 浩, 高梨 央康, 酒井 道代, 渋谷 弥生, 荒 香織, 岡村 知保, 石黒 奈々子, 秋庭 賢一, 大野 高志, 角藤 芳久

    日本精神科救急学会学術総会プログラム・抄録集　27回　141-141　2019年10月

    出版者・発行元： (一社)日本精神科救急学会

  44. OLIG2遺伝子多型(rs1059004)と自己スキーマ及び抑うつ症状との関連

    小松 浩, 竹内 光, 菊地 淑恵, 小野 千晶, 兪 志前, 飯塚 邦夫, 角藤 芳久, 舩越 俊一, 大野 高志, 川島 隆太, 瀧 龍之, 富田 博秋

    精神神経学雑誌　(2019特別号)　S452-S452　2019年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  45. オリゴデンドロサイト関連遺伝子多型(rs1059004)と自己スキーマ及び抑うつ症状との相関研究

    小松浩, 小松浩, 竹内光, 菊地淑恵, 小野千晶, 兪志前, 兪志前, 飯塚邦夫, 角藤芳久, 舩越俊一, 舩越俊一, 大野高志, 川島隆太, 川島隆太, 川島隆太, 瀧靖之, 瀧靖之, 瀧靖之, 富田博秋, 富田博秋, 富田博秋, 富田博秋

    日本うつ病学会総会プログラム・抄録集　16th　2019年

  46. 「重度かつ慢性」の基準案の該当及び非該当の入院患者の1年後、2年後転帰に関する調査

    小松 浩, 大野 高志, 米田 芳則, 高山 玲子, 森 康子, 藤田 享, 五十嵐 佳代子, 庄司 盟子, 本間 竜太, 大場 綾希子, 手代木 理, 槇 貴浩, 石田 雄介, 長谷 諭, 舩越 俊一, 角藤 芳久

    精神神経学雑誌　(2018特別号)　S562-S562　2018年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  47. OLIG2遺伝子多型(rs1059004)と統合失調症との関連,白質統合性,安静時脳潅流量及び認知機能への影響の検討

    小松浩, 竹内光, 菊地淑恵, 小野千晶, 角藤芳久, 舩越俊一, 大野高志, 山森秀長, 安田由華, 藤本美智子, 畦地裕統, 工藤紀子, 川島隆太, 橋本亮太, 橋本亮太, 瀧靖之, 富田博秋

    日本精神神経学会総会プログラム・抄録集　114th　(2018特別号)　S656-S656　2018年

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  48. 単科精神科病院で取り組む初回エピソード精神病へのチームアプローチ

    大野 高志、小松 浩、増子 俊、舩越 俊一、角藤 芳久、佐藤 祐太朗、松本 和紀

    予防精神医学　3　(1)　43-50　2018年

  49. IMPACT OF OLIG2 GENE VARIANT (RS1059004) ON WHITE MATTER TRACT INTEGRITY AND MEAN CEREBRAL BLOOD FLOW OF THE HUMAN BRAIN

    Hiroshi Komatsu, Hikaru Takeuchi, Yoshie Kikuchi, Akira Kodaka, Shunichi Funakoshi, Takashi Ono, Yoshihisa Kakuto, Ryuta Kawashima, Yasuyuki Taki, Hiroaki Tomita

    EUROPEAN NEUROPSYCHOPHARMACOLOGY　27　S315-S316　2017年10月

    ISSN： 0924-977X

    eISSN： 1873-7862

  50. 統合失調症慢性期における抗精神病薬減薬プロトコールの試み

    石田 雄介, 小松 浩, 佐藤 貴子, 岡嶋 みどり, 安達 健朗, 高橋 恵美, 三嶋 洋一, 鈴木 亮

    病院・地域精神医学　59　(1)　62-64　2016年9月

    出版者・発行元： 日本病院・地域精神医学会

    ISSN： 0910-4798

    詳細を見る 詳細を閉じる

    宮城県立精神医療センターにおいて、多職種で構成される抗精神病薬等適正使用検討部会を新たに立ち上げ、平成26年4月から平成27年3月に慢性期の患者群を対象にしたプロトコルに基づく抗精神病薬の減薬の試みを実施した。平成26年3月に実施した処方状況調査から、入院中の統合失調症患者のうち、診療報酬改訂の多剤基準を参考に抗精神病薬が4剤以上の患者を抽出し、研究に同意が得られた5名を対象とした。減薬対象者のうち、3剤以下までの減薬を達成したのは4名で、減薬途中での退院・転院が1名であった。症状悪化による減薬中止となった症例はなかった。平均減薬期間は10.8週で、抗精神病薬の平均剤数が4.4剤から3.2剤に減少した。平均CP換算量は1914.5mgから1736.0mgに減少した。今回の試みでは1回あたり1%未満のごく少量での減薬を行った。患者からは「何も変わらない」「もう少し早く減らしても大丈夫だと思う」などの感想が得られた。

  51. 【精神科治療における自殺:向精神薬のもたらすリスクとベネフィット】Aripiprazole単剤投与切り替えにより社会機能の改善と衝動的な自殺企図の減少をみた統合失調症の1例

    奥山 純子, 石田 雄介, 舩越 俊一, 小松 浩, 本多 奈美, 小高 晃

    臨床精神薬理　19　(8)　1161-1168　2016年8月

    出版者・発行元： (株)星和書店

    ISSN： 1343-3474

  52. リチウム投与下でのミクログリアと単球の遺伝子発現プロフィールの検討

    高橋 雄太, 兪 志前, 坂井 舞, 小松 浩, 伊藤 文晃, 松岡 洋夫, 富田 博秋

    精神神経学雑誌　(2016特別号)　S481-S481　2016年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  53. OLIG2遺伝子多型(rs1059004)が脳白質の神経線維束の拡散異方性及び安静時脳灌流量に及ぼす効果の検討

    小松 浩, 竹内 光, 菊地 淑恵, 小野 千晶, 坂井 舞, 小高 晃, 舩越 俊一, 大野 高志, 角藤 芳久, 高橋 雄太, 松岡 洋夫, 瀧 靖之, 川島 隆太, 富田 博秋

    精神神経学雑誌　(2016特別号)　S367-S367　2016年6月

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

  54. 統合失調症慢性期における抗精神病薬減薬プロトコールの試み

    石田 雄介, 小松 浩, 佐藤 貴子, 岡嶋 みどり, 安達 健朗, 高橋 恵美, 三嶋 洋一, 鈴木 亮

    日本病院・地域精神医学会総会抄録集　58回　46-46　2015年11月

    出版者・発行元： 日本病院・地域精神医学会

  55. Implementing an early intervention program for first-episode psychosis in a Japanese clinical setting: a preliminary descriptive study

    Takashi Ono, Akemi Kayama, Kazuko Saito, Syunichi Funakoshi, Yoshihisa Kakuto, Koichi Abe, Tatsui Otsuka, Ryo Nomura, Komatsu Hiroshi, Kazunori Matsumoto, Akira Kodaka, Hiroo Matsuoka

    EARLY INTERVENTION IN PSYCHIATRY　8　156-156　2014年11月

    ISSN： 1751-7885

    eISSN： 1751-7893

  56. FACS-arrayによる統合失調症罹患者のTh1およびTh2細胞の遺伝子発現プロファイリング

    小野千晶, 兪志前, 小松浩, 小松浩, 石井直人, 曽良一郎, 富田博秋

    統合失調症研究　2　(1)　2012年

  57. 双極性障害治療薬のアストロサイトにおける発現プロファイルへの影響

    兪 志前, 小野 千晶, 田邊 陽一郎, 小松 浩, 松岡 洋夫, 曽良 一郎, 富田 博秋

    Bipolar Disorder　9　13-14　2011年5月

    出版者・発行元： アルタ出版(株)

  58. 統合失調症罹患者のTh1およびTh2細胞のマイクロアレイ遺伝子発現プロファイリング

    小野千晶, 兪志前, 田邊陽一郎, 田邊陽一郎, 小松浩, 小松浩, 曽良一郎, 松岡洋夫, 石井直人, 富田博秋

    統合失調症研究　1　(1)　151-151　2011年

    出版者・発行元： 日本臨床精神神経薬理学会・日本神経精神薬理学会

  59. 気分安定薬バルプロ酸およびラモトリギン投与によるヒト脳細胞遺伝子発現変化のマイクロアレイ解析による包括的検討

    田邊 陽一郎, 田中 千晶, 兪 志前, 小松 浩, 木村 好, 羽藤 愛, 松岡 洋夫, 曽良 一郎, 富田 博秋

    Bipolar Disorder　8　61-69　2010年6月

    出版者・発行元： アルタ出版(株)

    詳細を見る 詳細を閉じる

    ニューロン由来のヒト神経細胞由来SK-N-SH細胞と、アストロサイト由来のU-87MG細胞、オリゴデンドロサイト由来のOL細胞を用いて、バルプロ酸とラモトリギン投与による脳細胞遺伝子発現変化を解析した。その結果、バルプロ酸はヒストン脱アセチル化酵素の遺伝子発現を抑制し、ラモトリギンは脳由来神経栄養因子や血管内皮増殖因子の遺伝子発現を促進することが確認された。

  60. 統合失調症罹患者のTh1およびTh2細胞のマイクロアレイ遺伝子発現プロファイリング

    小野千晶, 兪志前, 田邊陽一郎, 小松浩, 松岡洋夫, 曽良一郎, 石井直人, 富田博秋

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集　20th-40th　2010年

  61. 気分安定薬のアストロサイトにおける軸索誘導タンパク発現の誘導

    兪志前, 小野千晶, 田邊陽一郎, 田邊陽一郎, 小松浩, 小松浩, 松岡洋夫, 曽良一郎, 富田博秋

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集　20th-40th　124-124　2010年

    出版者・発行元： 日本臨床精神神経薬理学会・日本神経精神薬理学会

  62. 【統合失調症UPDATE】統合失調症における薬物治療 統合失調症における認知障害に対する非定型抗精神病薬の有効性

    松岡 洋夫, 小松 浩, 本多 奈美, 松本 和紀

    薬局　61　(1)　69-74　2010年1月

    出版者・発行元： (株)南山堂

    ISSN： 0044-0035

  63. 【痛みと遺伝子多型】遺伝子多型とオピオイドの副作用

    曽良 一郎, 小松 浩, 猪狩 もえ, 井手 総一郎, 池田 和隆, 下山 直人

    麻酔　58　(9)　1109-1111　2009年9月

    出版者・発行元： 克誠堂出版(株)

    ISSN： 0021-4892

  64. 気分安定薬奏功機序解明のための包括的遺伝子発現解析

    富田 博秋, 田中 千晶, 兪 志前, 小松 浩, 木村 好, 曽良 一郎, ヘレン・B.・キム, ウィリアム・E.・バニー

    臨床薬理の進歩　(30)　52-59　2009年7月

    出版者・発行元： (公財)臨床薬理研究振興財団

    ISSN： 0914-4366

    詳細を見る 詳細を閉じる

    気分安定薬4剤(リチウム、バルプロ酸、カルバマゼピン、ラモトリジン)を、ヒト脳内の3種の細胞(神経細胞、アストロサイト、オリゴデンドロサイト)に由来する各培養細胞に投与し、遺伝子発現プロファイルへの影響をマイクロアレイ解析により検討した。その結果、遺伝子発現プロファイルに対してリチウムとバルプロ酸は相互に比較的類似した影響を及ぼし、カルバマゼピンとラモトリジンは相互に比較的類似した影響を及ぼした。遺伝子発現プロファイルへの影響を3種の細胞ごとにみると、バルプロ酸は全ての細胞に比較的共通した発現変化をもたらしたのに対し、他の3剤による発現変化は細胞ごとに大きく異なった。

  65. 気分安定薬のアストロサイトにおける遺伝子発現変化の包括的検討

    兪志前, 田中千晶, 小松浩, 高橋怜史, 木村好, 曽良一郎, 富田博秋

    日本生物学的精神医学会プログラム・講演抄録　31st　2009年

  66. 気分安定薬リチウムの樹状細胞における遺伝子発現変化の包括的検討

    兪志前, 小野千晶, 田邊陽一郎, 田邊陽一郎, 小松浩, 小松浩, 木村好, 羽藤愛, 松岡洋夫, 曽良一郎, 富田博秋

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集　19th-39th　2009年

  67. ラモトリギン投与によるヒト脳由来細胞における包括的遺伝子発現の解析

    田邊陽一郎, 田邊陽一郎, 田邊陽一郎, 田中千晶, 愈志前, 小松浩, 小松浩, 木村好, 羽藤愛, 松岡洋夫, 曽良一郎, 富田博秋

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集　19th-39th　2009年

  68. 双極性障害治療薬の神経細胞およびグリア細胞における遺伝子発現変化の包括的検討

    兪志前, 田中千晶, 小松浩, 高橋怜史, 木村好, 富田博秋

    日本人類遺伝学会大会プログラム・抄録集　53rd　2008年

  69. 遺伝子多型検査によるテーラーメイド疼痛治療法の開発 疼痛治療個人差の遺伝子メカニズムに関する研究

    曽良一郎, 小松浩, 阿部裕美, 中野友美, 猪狩もえ, 長島誠, 田上惠, 福田謙一, 大谷保和, 笠井慎也, 井手聡一郎, 井手聡一郎, 林田眞和, 池田和隆

    遺伝子多型検査によるテーラーメイド疼痛治療法の開発 平成19年度 総括研究報告書　2008年

  70. 気分調整薬がヒト神経由来細胞およびグリア由来細胞の各BDNF転写物バリアント発現量に及ぼす影響の検討

    小松浩, 田中千晶, 兪志前, 木村好, 高橋さとし, 曽良一郎, 松岡洋夫, 富田博秋

    日本生物学的精神医学会プログラム・講演抄録　30th　2008年

  71. 遺伝子多型検査によるテーラーメイド疼痛治療法の開発 疼痛治療個人差の遺伝子メカニズムに関する研究

    曽良一郎, 曽良一郎, 小松浩, 阿部裕美, 中野友美, 猪狩もえ, 長島誠, 田上惠, 福田謙一, 大谷保和, 笠井慎也, 林田眞和, 村上敏文, 高橋秀徳, 井手聡一郎, 井手聡一郎, 下山直人, 池田和隆

    遺伝子多型検査によるテーラーメイド疼痛治療法の開発 平成17-19年度 総合研究報告書　2008年

  72. Chronic social defeat stressにおけるオピオイド神経伝達の役割

    小松浩, 小原可久, 服部寿妃, 阿部ひろみ, 畑春実, 曽良一郎

    日本生物学的精神医学会プログラム・講演抄録　29th　2007年

  73. 遺伝子多型検査によるテーラーメイド疼痛治療法の開発 癌性疼痛治療個人差の遺伝子メカニズムに関する研究

    曽良一郎, 小松浩, 村上敏文, 高橋秀徳, 阿部裕美, 井手聡一郎, 井手総一郎, 下山直人, 池田和隆

    遺伝子多型検査によるテーラーメイド疼痛治療法の開発 平成18年度 総括研究報告書　2007年

  74. 遺伝子多型検査によるテーラーメイド疼痛治療法の開発 癌性疼痛治療個人差の遺伝子メカニズムに関する研究

    曽良一郎, 曽良一郎, 小松浩, 山下元康, 村上敏史, 畑春実, 井手聡一郎, 井手聡一郎, 城戸幹太, 高橋雅彦, 糸川昌成, 沼知陽太郎, 小林秀昭, 下山直人, 池田和隆

    遺伝子多型検査によるテーラーメイド疼痛治療法の開発 平成17年度 総括研究報告書　2006年

  75. 精神疾患の分子病態解明による新しい治療・予防法の開発に関する研究 感覚運動情報処理制御の遺伝子改変マウスモデルおよびヒトPPI-PSIを用いた検討

    曽良一郎, 山下元康, 小林秀昭, 福島摂, 坂本修一, 中村真樹, 松岡洋夫, 鈴木陽一, 小松浩, 山本秀子, 池田和隆, 那波宏之, 沼知陽太郎

    厚生労働省精神・神経疾患研究委託費による研究報告集 平成16年度 (2年度班・初年度班)　2005年

  76. 未規制トリプタミン系薬物に関する乱用実態調査の試み

    小原可久, 沼知陽太郎, 小林秀昭, 山下元康, 渡辺秀和, 福島摂, 小松浩, 畑春実, 仲真樹, 近江香予, 曽良一郎

    精神神経学雑誌　107　(8)　903-903　2005年

    出版者・発行元： (公社)日本精神神経学会

    ISSN： 0033-2658

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 8

  1. 日本語版SSRMIの開発と検証に関する研究

    高濱 壮斗, 小松 浩, 内海 裕介

    2026年4月 ～ 2030年3月

  2. クロザピンによる炎症性副作用の遺伝学的基盤の解明

    伊藤 文晃, 小松 浩

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research

    研究種目：Grant-in-Aid for Scientific Research (C)

    研究機関：Tohoku University

    2025年4月1日 ～ 2028年3月31日

  3. 自閉症症状を伴う統合失調症の遺伝的・神経基盤の解明と病態層別化に関する研究

    小松浩, 金原信久

    2026年4月 ～ 2028年3月

  4. 認知矯正療法と運動療法の併用効果と個別化医療に向けた三次元眼底撮影による効果予測

    角藤 芳久, 内海 裕介, 富田 博秋, 小松 浩

    2022年4月1日 ～ 2027年3月31日

  5. 精神疾患横断的網膜イメージングによる個別化医療に向けた新たな診断基準の探求

    小野口豪

    2025年4月 ～ 2027年3月

  6. 網膜解析を中心とした早期治療抵抗性統合失調症の生物学的指標探索と脳神経基盤の解明

    小松 浩, 矢花 武史, 佐藤 祐太朗

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    研究種目：Grant-in-Aid for Scientific Research (C)

    研究機関：Tohoku University

    2022年4月 ～ 2026年3月

  7. 統合失調症と緑内障における網膜菲薄化・血管病態機序の異同解明を通した診療技術開発

    小松浩、塩澤慶明、曽良かおり、富田博秋

    2024年12月 ～ 2025年11月

  8. 精神科救急入院料病棟入院中からでも実施可能な双極性障害の簡易型集団心理教育の有効性と有効性に関わる要因の検討

    小松浩

    2021年4月 ～ 2022年3月

︎全件表示 ︎最初の5件までを表示

学術貢献活動 1

  1. Molecular Psychiatry, Schizophrenia Bulletin, Asian Journal of Psychiatry, Schizophrenia Research, Psychiatry and Clinical Neurosciences, Journal of Psychiatric Research, BMJ Open,

    学術貢献活動種別: 査読等